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ABSTRACT 
 
Hung-Ching Hsia: Roles and Regulation of STAT3 in Innate Immunity 
(Under the direction of Albert Baldwin) 
 
Innate immunity is the first line of host defense to microbial infections. The rapid 
induction of the innate immune response is achieved through recognition of pathogen-associated 
molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs). Upon 
recognition of PAMPs and DAMPs, cells initiate immune responses by expressing type I 
interferons (IFN) and interferon-stimulated genes (ISGs) to establish an antiviral and 
antimicrobial state, and by secreting cytokines and chemokines to recruit and activate immune 
cells such as macrophages and monocytes. These processes are precisely regulated to initiate a 
swift and effective defense against pathogens. 
My dissertation focuses on the roles and regulation of signal transducer and activator of 
transcription 3 (STAT3) in these responses. In the first project, I investigated the role of STAT3 
in myeloid cells with regards to innate immune responses during viral infection. We discovered 
that STAT3 knockout mice are more susceptible to herpes simplex virus-1 (HSV-1) due to an 
attenuated IFN response and to defects in dendritic cell and natural killer cell activation, 
revealing a requirement of STAT3 in eliciting an effective innate immune response against HSV-
1. The second project focused on dissecting the signaling pathways activated by cytosolic DNA, 
a DAMP, and the regulation of downstream transcription factors. I identified a novel signaling 
axis involving an inhibitory phosphorylation in STAT3 by TANK-binding kinase 1 (TBK1). 
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This TBK1-mediated phosphorylation restricts STAT3 activation and expression of selective 
STAT3 target genes in response to cytosolic DNA. Collectively, the research presented in this 
dissertation demonstrates a pivotal role of STAT3 in host innate immunity against viral infection, 
and uncovers a novel mechanism whereby the activity of STAT3 can be fine-tuned by innate 
immune response pathways. 
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CHAPTER 1: INTRODUCTION
1.1  STAT3 
1.1.1  General introduction 
Members of the signal transducer and transcription activator (STAT) family are dimeric 
transcription factors that regulate cellular differentiation, proliferation, survival, and immunity 
by responding to a variety of cytokines and growth factors. STAT proteins share the domain 
structure of an N-terminal domain (NTD) that promotes dimerization, followed by a DNA-
binding domain (DBD), an SRC-homology 2 (SH2) domain, and a C-terminal transactivation 
domain (TAD). Seven STAT genes have been identified in human and mouse, and STAT3 is the 
third member identified. Like other STAT family members, the activity of STAT3 is regulated 
by tyrosine phosphorylation, which facilitates STAT3 dimerization by interacting with the SH2 
domain within another STAT3 molecule. STAT3 is activated downstream of a number of 
cytokines and growth factors, such as leukemia inhibitory factor (LIF), IL-6, IL-10, and 
epidermal growth factor (EGF) (1,2). The most well known activators of STAT3 are the IL-6 
family cytokines, with IL-6 being the prototype. Binding of IL-6 to the IL-6 receptor associated 
with the transmembrane protein gp130 activates Janus kinase 2 (JAK2), one of the four kinases 
in the JAK family. Activated JAK2 subsequently phosphorylates Y705 of STAT3, facilitating its 
dimerization and activation. Similarly, type I interferons (IFN) also induce STAT3 activation 
through JAKs, while EGF and other growth factors activate STAT3 by receptor tyrosine kinases 
(RTKs) and SRC (3,4). Recent studies revealed that a sphingolipid, spingosine-1-phosphate 
(S1P) also activates STAT3 via G-protein coupled receptor (GPCR) and JAK2 (5). 
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Unphosphorylated STAT3 exists as stable dimers prior to activation because of the homotypic 
interaction mediated by the NTDs of two STAT3 molecules, but inactive STAT3 dimers are 
constantly being shuttled in between the nucleus and the cytoplasm (6-9). While activated, Y705 
phosphorylation enhances the DNA binding activity of STAT3 and thus the nuclear retention 
(8,10). Active STAT3 homodimers bind to a 9-bp palindromic sequence with the consensus of 
TTCNNNGAA (11). However, this gamma-interferon activating sequence (GAS) recognized by 
STAT3 is very similar to that of STAT1. In fact, STAT3 and STAT1 share identical optimal 
GAS sequence when analyzed in vitro, but variation in endogenous core and flanking sequences 
leads to differential recognition by STAT1 and STAT3, resulting in distinct but overlapping 
target genes controlled by STAT1 and STAT3 (12,13). In the nucleus, STAT3 promotes the 
transcription of genes involved in inflammation, survival, and cell cycle, such as C-C motif 
ligand 2 (CCL2), Bcl-xL, metallomatrix protease 2 (MMP2), Survivin, and Cyclin D1 (4) 
(Figure 1.1). With target genes involved in these essential cellular processes, constitutive 
activation of STAT3 has been implicated in tumorigenesis and various types of cancers 
(4,14,15), as discussed in the following paragraphs. 
 
1.1.2  STAT3 in human diseases 
Dysregulation of STAT3 has profound implications in human diseases. For example, 
germline dominant negative STAT3 mutations have been identified in patients with autosomal 
dominant hyper IgE syndrome (AD-HIES), an immunodeficiency disorder. AD-HIES patients 
are characterized by symptoms such as elevated serum IgE titer, increased TNFα and IL-12 
production from leukocytes, susceptibility to recurrent bacterial and fungal pneumonia, and 
impaired ability to control herpesvirus latency (16,17). Similarly, in mice, targeted deletion of 
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STAT3 in myeloid cells results in elevated TNFα and IL-12 in response to bacterial components 
and susceptibility to bacterial infections (18,19). These mice are also more susceptible to herpes 
simplex virus-1 (HSV-1) infection, as discussed in Chapter 2 of this dissertation (20). 
Conversely, somatic activating mutations of STAT3 have been associated with 
lymphoproliferative disorders and hepatocellular adenomas (21-23), whereas germline activating 
mutations of STAT3 contribute to early-onset autoimmune disorders that affect multiple organs 
(24), underscoring dysregulated STAT3 activation as a causative factor in enhanced cell 
proliferation and aberrant activation of immune cells. 
 Constitutive activation of STAT3 has been documented in many types of cancers, and the 
consequences of such dysregulation are multifaceted. Through target genes involved in 
inflammation, anti-apoptosis, cell cycle, and invasion and migration, STAT3 supports 
tumorigenesis, survival, proliferation, and metastasis of cancer cells (4,25,26). Expression of a 
constitutively active STAT3 mutant is sufficient to transform immortalized cells (14,27). In K-
RAS driven pancreatic cancers, STAT3 is required for the initiation and progression of 
tumorigenesis (28), although studies have reported conflicting roles of STAT3 in K-RAS driven 
lung cancers (29,30). Elevated STAT3 activity in glioblastoma and prostate cancer correlates 
with cancer stem cell-like properties, including enhanced tumorigenecity and resistance to 
therapy (31,32). STAT3 also promotes metastasis by upregulating genes implicated in migration 
and invasion in tumor cells (33), and by priming and preparing fibroblasts at distal sites for 
metastatic cancer cells (34). STAT3 often fuels inflammation, exacerbates inflammation-
associated cancers, and promotes survival of cancer cells in collaboration with nuclear factor-
kappaB (NF-κB). The interaction between STAT3 and NF-κB occurs at several levels. For one, 
STAT3 and NF-κB share overlapping target genes, including anti-apoptotic genes and 
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inflammatory cytokines (15). STAT3 physically interacts with NF-κB and retains NF-κB in the 
nucleus for sustained activation and expression of IL-6, which further activates STAT3 and 
forms an amplification loop (35-39). Finally, STAT3 inhibits the expression of 
immunostimulatory genes in cancer cells (40), and induces the expression of IL-23 to activate 
regulatory T cells (Treg) in the tumor microenvironment, thereby dampening the anti-tumor 
immune responses through a concerted effort (41). Moreover, IL-10 from tumor cells inhibits 
activation of immune cells via STAT3 signaling, and genetic deletion of STAT3 in 
hematopoietic cells enhances anti-tumor immunity, demonstrating an immunosuppressive role of 
STAT3 in the tumor microenvironment (42,43). 
 
1.2  TBK1 and IKKε  
1.2.1  General introduction 
NF-κB is a family of dimeric transcription factors comprising five subunits: p65 (RelA), 
p100/p52, p105/p50, RelB, and c-Rel. In the canonical NF-κB pathway, the activity of the p65-
p50 dimer is tightly regulated by inhibitor of kappaB (IκB) and two IκB kinases (IKKs), IKKα 
and IKKβ. Under basal conditions, the p65-p50 NF-κB dimers are inactive and bound by IκBα in 
the cytosol. Various environmental cues and cytokines such as IL-1 and TNFα can lead to 
activation of the IKK complex comprising of IKKα, IKKβ, and IKKγ (NF-κB essential 
modifier/NEMO). The activated IKK complex phosphorylates IκBα at S32 and S36, which 
triggers proteasome-dependent degradation of IκBα. The liberated p65-p50 dimers then 
translocate to the nucleus and activate transcription of target genes involved in inflammation and 
survival, such as IL-6 and Bcl-xL, and genes involved in the negative feedback of NF-κB, such 
as A20 and IκBα. In the non-canonical pathway, RelB-p100 dimers are inactive due to the 
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inhibitory ankyrin repeats in p100 subunit. Phosphorylation of p100 by IKKα induces 
proteasomal processing of p100 into p52, resulting in the active RelB-p52 dimers (Reviewed in 
(44)). Genetic experiments demonstrated that the IKKs, especially IKKβ, are required for NF-κB 
activation by lipopolysaccharide (LPS), IL-1, and TNFα (45-47). Following the identification of 
IKKα and IKKβ, two more related kinases were identified. TANK-binding kinase 1 (TBK1) was 
originally identified in a screen for proteins interacting with TANK, a TRAF-binding protein that 
modulates TRAF-mediated NF-κB signaling (48), and IKKε was identified as an IKK-related 
kinase whose expression can be highly induced by LPS (49). The sequences of TBK1 and IKKε 
share approximately 50% identity with each other, and approximately 30% identity with IKKα 
and IKKβ (50). The domain structures of TBK1 and IKKε are similar to IKKα and IKKβ, but 
TBK1 and IKKε lack the NEMO-binding domain in the C terminus. 
 
1.2.2  TBK1 and IKKε in innate immunity 
Unlike IKKα and IKKβ that phosphorylate both S32 and S36 of IκBα, TBK1 and IKKε 
only phosphorylate S32 of IκBα in in vitro assays (49,51), and TBK1 and IKKε are not required 
for IκBα degradation or NF-κB activation induced by IL-1 and TNFα (48,49). While dispensable 
for IL-1 and TNFα-induced NF-κB activation, TBK1 is required for the induction of the type I 
IFN in response to a variety of pathogen-associated or danger-associated molecular patterns 
(PAMPs and DAMPs), including poly (I:C), intracellular double-stranded DNA (dsDNA), LPS, 
and viral infections, whereas IKKε has minimal or redundant functions in these scenarios (52-
56). As an interferon-stimulated gene (ISG) itself, IKKε plays a more significant role at the late 
stage of IFN response after its expression is upregulated by the first wave of IFN (57). PAMPs 
and DAMPs activate TBK1 and IKKε through engagement of an array of toll-like receptors 
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(TLRs) and TLR-independent receptors (58). In general, the activating signals from these 
receptors lead to the assembly of ubiquitin ligase complexes, which bind to and K63-ubiquitinate 
TBK1 and IKKε. The K63-polyubiquitin chains then cooperate with ubiquitin binding proteins to 
promote TBK1 and IKKε oligomerization and facilitate their autophosphorylation (59-63). Once 
activated by autophosphorylation, TBK1 and IKKε mediate IFN expression by directly 
phosphorylating interferon regulatory factors IRF3 and IRF7 at a number of serine residues, 
allowing IRFs to homodimerize and translocate to the nucleus to induce type I IFN transcription 
(52,64). In addition to its pivotal role in IFN induction, TBK1 also promotes autophagy-mediated 
clearance of intracellular bacteria by phosphorylating adaptors that target bacteria for the 
autophagosome (65,66). With their ability to respond to the presence of PAMPs and DAMPs to 
induce IFN expression and autophagy, TBK1, and to a lesser extent IKKε, are critical molecules 
that establish the first line of host defense against pathogens at the cellular level. 
 
1.2.3  TBK1 and IKKε in cancers 
In addition to their well-established roles in initiating IFN responses, several studies 
reported an oncogenic role for TBK1 and IKKε. An RNAi screening showed that KRAS-
transformed cancer cell lines require TBK1-mediated activation of NF-κB and transcription of 
anti-apoptotic genes for survival (67). TBK1 also inhibits oncogenic stress-induced apoptosis via 
NF-κB independent pathways (68,69). Similarly, IKKε is often overexpressed or amplified in 
human breast cancers (70), and inhibition of IKKε in related breast cancer cell-lines results in 
halted growth and cell death (70,71). IKKε facilitates oncogenesis by indirectly promoting NF-
κB activity through phosphorylating and inhibiting CYLD, a negative regulator of the NF-κB 
pathway (72). 
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1.3  Responses Elicited by Cytosolic DNA 
The subcellular compartmentalization of mammalian cells normally sequesters DNA in 
the nucleus and mitochondria. DNA in the cytosol is thus a DAMP that signals abnormality and 
triggers cell-intrinsic immune responses (56,73). Cytosolic DNA can be derived from self-DNA 
in normal physiological conditions, such as phagocytosed materials, including dead cells and 
ejected nuclei from erythroid precrusors, or re-activated endogenous retroelements. Additionally, 
viral or intracellular bacterial infections lead to the presence of foreign DNA in the cytosol (74). 
Recognition of cytosolic DNA by cellular sensors leads to activation of two major pathways: (i) 
inflammasome-driven mechanisms that produce IL-1β and IL-18, and (ii) IRF activation that 
induces IFN expression. The major players in the cytosolic DNA pathway are introduced in the 
following paragraphs, with emphases on the IFN response (Figure 1.2). 
 
1.3.1  Induction of the inflammasomes by cytosolic DNA 
The inflammasome is a molecular complex that regulates the activation of caspase-1 and 
induces inflammation in response to a variety of PAMPs and DAMPs. Assembly of 
inflammasomes is mediated by polymerization of apoptosis-associated speck-like protein 
containing a CARD (ASC) proteins and the subsequent recruitment of pro-caspase 1. After self-
activating proteolytic cleavage, caspase 1 processes the cytokine precursors pro-IL-1β and pro-
IL-18 into active IL-1β and IL-18 (75). Cytosolic DNA induces IL-1β and IL-18 secretion 
through inflammasome formation mediated by the protein absent in melanoma 2 (AIM2). AIM2 
is a member of the Pyrin and HIN domain (PYHIN) family (76-78) and binds to dsDNA directly 
via its HIN domain. The Pyrin domain and HIN domain of AIM2 form an autoinhibitory 
conformation via intramolecular interaction under basal conditions, but direct dsDNA binding by 
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the HIN domain liberates the Pyrin domain, allowing it to interact with ASC. Using a DNA 
molecule as a platform, multiple AIM2 proteins bind to and nucleate on the DNA, thereby 
facilitating the polymerization of ASC and the formation of inflammasomes in response to 
cytosolic DNA (77-79). 
 
1.3.2  Induction of interferons by cytosolic DNA 
While detection of cytosolic DNA by AIM2 induces inflammasome formation through 
polymerization of the adaptor ASC, other cytosolic DNA sensors engage different adaptor 
proteins to promote TBK1 and IRF3 activation, thereby leading to interferon production. The 
roles of various cytosolic DNA sensors and the quintessential adaptor stimulator of interferon 
genes (STING) in cytosolic DNA-induced IFN response are discussed as follows. 
STING. It has been known that introduction of foreign DNA into the cytosol triggers 
TBK1-mediated IFNβ production, but it was unclear how TBK1 becomes activated (56,73). It 
was later found that an ER resident protein STING, encoded by the TMEM173 gene, is a critical 
adaptor required to activate TBK1 upon cytosolic DNA challenge (80-82). Structural and in vitro 
analyses suggested that STING does not act as a DNA sensor in the cells (83,84). Instead, it 
binds to cyclic GMP-AMP (cGAMP) generated by the DNA-dependent cytosolic enzyme cyclic 
GMP-AMP synthase (cGAS) (85). Binding to cGAMP induces STING oligomerization and 
enhances its interaction with TBK1 (85), thereby promoting TBK1 autophosphorylation and 
activation, presumably by increasing the local concentration of TBK1 (62). Active TBK1 
subsequently phosphorylates the C terminus of STING, creating a docking site for recruiting 
IRF3, which is then phosphorylated and activated by TBK1 (86-88). Interestingly, STING seems 
to be a convergence point for the cytosolic DNA pathway, because it is also required for an IFN 
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response mediated by other cytosolic DNA sensors, such as IFI16 and DDX41 (83,89). In 
addition to cGAMP, STING also recognizes other cyclic di-nucleotides (CDNs) generated by 
bacteria (90,91). Therefore, STING has an integral role in defending against intracellular 
bacterial infection by directly sensing bacterial CDN and by indirectly responding to bacterial 
DNA via cGAS. Several frequent single nucleotide polymorphisms (SNPs) have been identified 
in the human TMEM173 allele. These SNPs lead to amino acid substitutions that decrease the 
affinity of STING to bacterial CDNs, and may have implications in the susceptibility to bacterial 
diseases and autoimmunity of different individuals (92,93).  
IFI16. Similar to AIM2, interferon-gamma inducible protein 16 (IFI16) is a member of 
the PYHIN family. IFI16 interacts with STING upon binding to DNA via its two HIN domains, 
and promotes IRF3 and NF-κB activation in a STING-dependent manner (83). IFI16 is unique 
because of its cytoplasmic and nuclear distribution, with nuclear localization being predominant 
(78,83,94). This unique distribution pattern allows IFI16 to detect foreign DNA not only in the 
cytoplasm but also in the nucleus. Indeed, IFI16 limits HSV-1 replication by targeting naked 
HSV-1 DNA genome in the nucleus for heterochromatinzation and silencing (95). However, 
nuclear IFI16 has to discriminate self-DNA from foreign DNA to prevent self-reactivity. 
Biochemical studies revealed that the cooperative binding mechanism of IFI16 to DNA is the 
key to its selectivity (96). The two HIN domains of IFI16 bind to dsDNA with a mild affinity 
independent of the DNA sequences, while the Pyrin domain promotes cooperative binding 
between the two HIN domains. As a result, IFI16 selectively oligomerizes on naked DNA over 
~150 bp in length with very high affinity and efficiency (96), allowing IFI16 to preferentially 
bind to naked foreign DNA even in the presence of excessive self-DNA that is chromatinized. 
  10 
ZBP1. Z-DNA binding protein 1 (ZBP1) is a DNA-binding protein that was initially 
identified in macrophages as being encoded by an IFN-inducible gene (97,98). A cytosolic 
protein, ZBP1 binds to cytosolic dsDNA and contributes to optimal IFN expression in MEFs and 
L929 cells by promoting TBK1-IRF3 interaction (99). ZBP1 also contributes to IFN responses 
and resistance to cytomegalovirus, a DNA virus (100). However, it is unlikely that ZBP1 is the 
principle cytosolic DNA sensor, since genetic deletion of ZBP1 has minimal impact on the 
ability of cells to respond to cytosolic DNA (83,101). 
DDX41. The DEAD-box helicase 41 (DDX41) protein has been demonstrated to 
participate in the cytosolic DNA-induced IFN response in dendritic cells (89). DDX41 binds to 
dsDNA through its DEAD-box domain, and interacts and colocalizes with STING upon dsDNA 
transfection (89). It was later shown that Bruton’s tyrosine kinase (BTK) phosphorylates DDX41 
and induces its binding with STING upon cytosolic dsDNA stimulation, leading to activation of 
the TBK1-IRF3 signaling axis (102). Moreover, DDX41 also binds to cyclic di-GMP and cyclic 
di-AMP with even higher affinity than STING, and is required for cyclic di-GMP and cyclic di-
AMP-induced, STING-dependent IFN responses (103). It is worth noting that while expression 
of IFI16 and ZBP1 remains low unless induced by IFNs, the constitutive expression of DDX41 
in cells such as DCs and monocytes suggest a critical role for DDX41 in the first line of cytosolic 
DNA sensing. 
RNA polymerase III. STING has an essential role in IFN expression induced by 
cytosolic DNA regardless of DNA sequences or sources with one exception (104). Transfection 
of poly(dA:dT) induces moderate IFN expression even in the absence of STING (104), 
suggesting the existence of STING-independent cytosolic DNA pathways specific to AT-rich 
dsDNA. Two groups independently discovered that cytosolic poly(dA:dT) is detected and 
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transcribed by RNA polymerase III in the cytosol (105,106). The resulting 5’ triphosphate-
capped RNA products are recognized by retinoic acid inducible gene-I (RIG-I), thereby inducing 
IFN expression through a mitochondrial antiviral signaling protein (MAVS)-dependent 
mechanism (105,106).  
cGAS. While the aforementioned cytosolic DNA sensors are all involved in relaying the 
presence of cytosolic DNA to IFN induction, knockdown of individual sensors rarely achieves 
complete abrogation of cytosolic DNA-induced IFN, indicating redundancy between these 
cytosolic DNA sensors. Moreover, their inducible expression (IFI16, ZBP1), limited distribution 
pattern in specific cell types (DDX41), and specificity toward AT-rich substrates (RNA Pol III) 
suggested the existence of additional unidentified cytosolic DNA sensors that are more 
ubiquitously expressed and less sequence-specific in DNA recognition. The identification of 
cGAS (encoded by the MB21D1 gene) provides a missing piece to this puzzle. cGAS is a 
cytoplasmic nucleotidyltransferase with dsDNA-dependent enzymatic activity. The enzymatic 
core of cGAS catalyzes the formation of cyclic GMP-AMP (cGAMP) using GTP and ATP as 
substrates, whereas the C-terminal domain interacts with DNA (107-110). cGAS specifically 
binds to DNA but not RNA, with strong preference to dsDNA over ssDNA in a sequence-
independent manner (108). Structural changes induced by dsDNA binding activate cGAS to 
produce a non-canonical cGAMP, [G(2’-5’)pA(3’-5’)], which in turn binds to and activates the 
downstream adaptor STING, thereby initiating the STING-TBK1-IRF3 signaling cascade and 
IFN responses (108-113). Genetic deletion of cGAS abrogates the IFN response of a number of 
cell types to cytosolic DNA with different sequence compositions, suggesting that cGAS has a 
more universal and critical role in the cytosolic DNA pathway comparing to other sensors (114). 
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1.3.3  Induction of the NF-κB pathway by cytosolic DNA 
 In addition to type I IFN, cytosolic DNA also activates NF-κB in a STING-depedent 
manner. STING overexpression is sufficient to activate NF-κB, whereas STING deficiency 
abolishes cytosolic DNA-induced NF-κB activation (81,104). Further studies demonstrated that 
both canonical (p65-p50) and non-canonical (RelB-p52) NF-κB are activated downstream of 
STING, and NF-κB is required for IL-6 expression and contributes to IFNβ expression induced 
by cytosolic DNA (115). Activation of NF-κB requires IKKα, IKKβ, and the E3 ligases TRAF3 
and TRAF6 but, depending on the cell type, TBK1 may or may not be required for activation of 
IKKβ by cytosolic DNA ((115) and Chapter 3).  
 
1.3.4  Cytosolic DNA and autoimmunity 
Clearance of self-DNA in the cytosol under physiological conditions is achieved by 
DNases in the cytosol and lysosome, and failure to clear self-DNA causes substantial 
inflammatory and IFN responses as well as autoimmune conditions. For example, loss-of-
function mutations of cytosolic DNase III (3’ repair exonuclease 1, TREX1) have been identified 
as a causative factor of the neurological autoimmune disease Aicardi-Goutières Syndrome 
(AGS) (116,117). Genetic manipulation in mice showed that deletion of lysosomal DNase II 
results in accumulation of undigested nuclei in liver macrophages and embryonic lethality 
characterized by unchecked interferon and inflammatory responses, and that deletion of TREX1 
leads to severe autoimmune conditions recapitulating the symptoms in human diseases (118-
122). The etiological role of cytosolic DNA in these scenarios is demonstrated by rescue 
experiments, whereby deletion of cGAS or STING can rescue the autoimmunity observed in 
these DNase-deficient mice (123-127). 
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1.3.5  Cytosolic DNA and microbial infections 
Cytosolic DNA can also arise from viral or intracellular microbial infections. The DNA 
genome of herpesvirus and vaccinia virus, as well as the reverse-transcribed HIV DNA, are 
recognized by intracellular DNA sensors, thereby triggering IFN responses and host antiviral 
mechanisms (83,100,114,128-133). Not surprisingly, a number of viral proteins have been 
identified by their ability to target and inhibit the cytosolic DNA pathway to evade host immune 
surveillance (Reviewed in (134)). Interestingly, an unbiased screening revealed that in addition 
to its role in controlling DNA virus pathogenesis, cGAS also contributes to limiting RNA virus 
replication (135). This suggests an unidentified mechanism by which viral RNA activates cGAS. 
Alternatively, it is possible that low levels of cGAS activation by self-DNA pre-establish a 
suboptimal antiviral state, such that cGAS deficiency makes cells more susceptible to RNA virus 
infection. Intracellular bacteria, such as Mycobacterium tuberculosis, induce IFNβ production in 
a cGAS-STING-dependent manner (136,137). Activation of TBK1 in this scenario also induces 
ubiquitin-mediated autophagy that targets the M. tuberculosis to lysosome for degradation, 
thereby serving as an important tool in controlling intracellular mycobacteria replication (138). 
Similarly, intracellular infection of Legionella, Listeria, and Francisella all engage the cytosolic 
DNA pathway, while Listeria also produces cyclic-di-AMP that directly activates STING 
(136,139-141). 
 
1.4  Regulation of STATs by Innate Immune Signaling Pathways 
Recent studies identified several novel mechanisms that regulate activity of STATs by 
innate immune signaling pathways. For example, TBK1 and STING-mediated phosphorylation 
of the STAT6 DNA binding domain (DBD) is required for virus-induced STAT6 activation, 
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which promotes efficient antiviral responses by inducing CCL2, CCL20, and CCL26 (142). Type 
I IFN (IFNα and IFNβ) induces STAT1 homodimers to promote GAS-driven gene expression, 
while type II IFN (IFNγ) induces STAT1-STAT2-IRF9 heterotrimers, which bind to the 
interferon-stimulated response element (ISRE) and promote a different ISG expression profile. 
IKKε fine-tunes the balance between GAS-driven and ISRE-driven ISGs by phosphorylating 
S708 of STAT1. This phosphorylation disrupts STAT1 homodimerization and favors the 
heterotrimer formation, thereby shifting the IFN-induced gene expression profile toward ISRE-
driven ISGs (143,144). It has also been noted that STING deficiency in autoimmune-prone mice 
leads to hyperactivation of STAT1-mediated IFN responses and exacerbated autoimmunity 
symptoms, suggesting a negative role of STING in regulation of STAT1 (145). This regulation 
may be partially mediated by the ability of STING to activate SH2 domain-containing 
phosphatases (SHPs), which dephosphorylate and inactivate STAT1 (146). Finally, my work 
presented in Chapter 3 reveals another signaling axis, in which TBK1 phosphorylates STAT3 at 
S754 in the transactivation domain (TAD) to restrict STAT3 activity in response to cytosolic 
DNA. 
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Figure 1.1  A schematic overview of the STAT3 pathway 
Preformed STAT3 dimers are constantly being shuttled between the nucleus and the cytoplasm 
unless activated. STAT3 can be activated by growth factors, several families of interleukins such 
as IL-6 and IL-12, sphingosine-1-phosphate (S1P), and type I IFNs. Receptor engagement of 
these ligands induces STAT3 Y705 phosphorylation by receptor tyrosine kinases (RTK), SRC, 
or Janus kinases (JAK). Phosphorylated STAT3 dimers have enhanced DNA binding affinity and 
stay in the nucleus, bind to the gamma-activated sequence (GAS) in the promoters, and drive the 
expression of target genes, such as CCL2, MMP9, Bcl-xL, and Cyclin D1. 
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Figure 1.2  Signaling pathways induced by cytosolic DNA 
The presence of cytosolic DNA is detected by a variety of sensors: cGAS, IFI16, DDX41, AIM2, 
and RNA polymerase III. While AIM2 induces inflammasome formation and RNA polymerase 
III activates the dsRNA pathway, the other sensors engage STING to activate TBK1, leading to 
IRF3 phosphorylation and IFNβ production. IFNβ establishes an antiviral state through 
activation of STAT1 and expression of IFN-stimulated genes (ISGs). Additionally, TBK1 also 
promotes NF-kB and STAT6 activation, but restricts IL-6 and IFNβ-mediated STAT3 activation 
(Chapter 3). The red arrows denote serine phosphorylation, and the blue arrows denote tyrosine 
phosphorylation. 
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CHAPTER 2: STAT3 REGULATES HOST DEFENSE AND PROTECTS MICE 
AGAINST HERPES SIMPLEX VIRUS-1 INFECTION1  
2.1  Summary 
Signal transducer and activator of transcription 3 (STAT3) mediates cellular responses to 
multiple cytokines, governs gene expression, and regulates the development and activation of 
immune cells. STAT3 also modulates reactivation of latent herpes simplex virus-1 (HSV-1) in 
ganglia. However, it is unclear how STAT3 regulates the innate immune response during the 
early phase of HSV-1 lytic infection. Many cell types critical for the innate immunity are derived 
from the myeloid lineage. Therefore, here we used myeloid-specific STAT3 knockout mice to 
investigate the role of STAT3 in the innate immune response against HSV-1. Our results 
demonstrated that STAT3 knockout bone marrow-derived macrophages (BMMs) expressed 
decreased levels of Interferon α (IFNα) and interferon-stimulated genes (ISGs) upon HSV-1 
infection. In vivo, knockout mice were more susceptible to HSV-1, as marked by higher viral 
loads and more significant weight loss. Splenic expression of IFNα and ISGs was reduced in the 
absence of STAT3, indicating that STAT3 is required for optimal type I interferon response to 
HSV-1. Expression of TNFα and IL-12, cytokines that have been shown to limit HSV-1 
replication and pathogenesis, was also significantly lower in knockout mice. Interestingly, 
STAT3 knockout mice failed to expand CD8+ conventional DC (cDC) population upon HSV-1 
                                                
1 This chapter has been accepted by the Journal of Leukocyte Biology and is placed into this 
dissertation after additional editing by the author. The original citation is as follows: Hsia H-C, 
Stopford CM, Zhang Z, Damania B, Baldwin AS. Signal transducer and activator of transcription 
3 (Stat3) regulates host defense and protects mice against herpes simplex virus-1 (HSV-1) 
infection. Journal of Leukocyte Biology. 2016 Dec 13 (In press) 
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infection, and this was accompanied by impaired NK and CD8 T cell activation. Collectively, 
our data demonstrated that myeloid-specific STAT3 deletion causes defects in multiple aspects 
of the immune system, and that STAT3 has a protective role at the early stage of systemic HSV-
1 infection. 
 
2.2  Introduction 
Herpes simplex virus 1 (HSV-1) is estimated to infect more than two thirds of the 
population worldwide. Common symptoms of HSV-1 infection, including local skin or mucosa 
membrane lesions, usually resolve in a few days to several weeks (1). Localized HSV-1 
infections are also often accompanied by viremia (2,3). Following lytic infection, the virus 
retreats to neurons where it establishes latency. Latency is lifelong and may be asymptomatic 
with occasional relapses (1). HSV-1 infection seldom causes severe disease in healthy 
individuals. However, newborns, the elderly, and immunocompromised individuals are prone to 
HSV-1-induced diseases, such as herpes simplex keratitis (HSK) and life-threatening herpes 
simplex encephalitis (HSE) (1). These susceptible populations also are more likely to exhibit 
HSV-1 viremia in the blood (2), and it is now becoming more apparent that primary HSV-1 
infection and reactivation can occur beyond the mucocutaneous areas in both immunocompetent 
and immunocompromised individuals (2). It is therefore important to understand the mechanism 
by which the immune system controls HSV-1 infection. 
Both innate and adaptive immunity are critical in controlling HSV-1 infection. Several 
major cellular mediators of the innate immunity implicated in limiting HSV-1 pathogenesis are 
of the myeloid lineage, including macrophages, dendritic cells (DCs), and neutrophils. 
Macrophages are intrinsically resistant to productive HSV-1 infection (4,5). Depletion of 
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macrophages in mice leads to higher viral replication and exaggerated pathology (6,7), while 
adoptive transfer of adult macrophages protects susceptible neonates from lethal HSV-1 
infection (8). Macrophages also limit the replication and dissemination of HSV-1 in the 
peripheral nervous system (9). The protective effects of macrophages are partially mediated 
through secreted factors, including IL-12, TNFα, and nitric oxide (NO). These factors inhibit 
viral replication, recruit leukocytes to the site of infection, promote the cellular immune 
response, and further activate macrophages to protect mice from HSV-1 and other herpesvirus 
infections (9-13). Specialized macrophages such as marginal zone macrophages (MZMΦs) and 
marginal metallophilic macrophages (MMMΦs) produce substantial amount of type I interferons 
to elicit antiviral response during HSV-1 viremia (14).  In addition to macrophages, dendritic 
cells (DCs) also play a pivotal role in the immunity against herpesvirus infections. Mice depleted 
of DCs have shortened survival and higher viral loads in the nervous system during HSV-1 
infection, and the susceptibility is attributed to impaired NK and T cell activation in the absence 
of DCs (15). Major subsets of DCs include CD11b+ conventional DC (cDC), CD8+ cDC, and 
plasmacytoid DC (pDC). Both CD8+ cDC and pDC are involved in promoting NK cell activation 
and anti-HSV cytotoxic T lymphocyte (CTL) immunity (16-18), but only CD8+ cDC is able to 
cross present and directly activate CD8 T cells (19,20). Importantly, pDCs are capable of 
producing large quantities of type I interferons during HSV-1 infection (17). Finally, neutrophils 
have dual roles in HSV-1 infection. It has been suggested that neutrophils inhibit HSV-1 
replication (21), but further examination revealed that neutrophils mediate HSV-1-induced tissue 
injury and immunopathology (22,23). 
Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that 
mediates the cellular responses to multiple cytokines by promoting the expression of genes 
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implicated in survival, inflammation, proliferation, and migration (24). STAT3 modulates HSV-
1 reactivation in the ganglia (25) and governs various aspects of myeloid cell proliferation, 
differentiation, and responses to infections (26-29). For example, STAT3-null macrophages 
display heightened immune responses in response to lipopolysaccharide (LPS) and bacterial 
infections, as marked by the overproduction of pro-inflammatory cytokines (26,30). 
Additionally, STAT3-null neutrophils are defective in their bactericidal capacity (30). 
Nonetheless, the role of STAT3 in the myeloid lineage during viral infections has not been fully 
investigated.  
Given the critical role of macrophages and DCs in limiting HSV-1 pathogenesis at the 
early phase of infection, we set out to investigate if STAT3 in the myeloid lineage modulates the 
innate immune response to HSV-1. Here we show that the type I interferon response was 
partially defective in STAT3-null bone marrow-derived macrophages (BMMs) during HSV-1 
infection. In vivo, myeloid STAT3 knockout mice exhibited higher viral loads and more 
significant weight loss during HSV-1 infection compared to wild-type mice. Importantly, 
knockout mice had decreased splenic expression of IFNα and interferon-stimulated genes (ISGs), 
as well as decreased expression of IL-12 and TNFα, cytokines known to be protective against 
HSV-1 infection. Finally, STAT3 knockout mice failed to expand CD8+ cDC during HSV-1 
infection, and activation of natural killer (NK) and CD8 T cells was also impaired. In summary, 
our results indicate that STAT3 in the myeloid lineage contributes to the resistance to HSV-1 
infection at the early stage by modulating multiple aspects of innate immunity. 
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2.3  Results 
2.3.1  Characterization of Stat3fl/fl LysM-Cre+/+ mice 
To investigate if STAT3 in the myeloid lineage affects the innate immune response to 
HSV-1, we crossed Stat3fl/fl mice to LysM-Cre mice to generate myeloid-specific STAT3 
knockout mice. Cre recombinase driven by the lysozyme (LysM) promoter is specifically 
expressed in the myeloid lineage, leading to conditional deletion of loxP-flanked target gene in 
granulocytes, monocytes, and macrophages (31). In agreement with the literature, bone marrow-
derived macrophages (BMMs) from Stat3fl/fl LysM-Cre+/+ mice (hereafter referred as knockout 
mice) showed more than 90% reduction of STAT3 protein comparing to BMMs from Stat3wt/wt 
LysM-Cre+/+ mice (hereafter referred as wild-type mice). No noticeable reduction of STAT3 
protein levels were observed in the brain, liver, or muscle as determined by immunoblotting 
(Supplemental Figure 2.1). 
The Stat3fl/fl used in this study (see Materials and Methods) differs from the strain used in 
the previous LysM-Cre/Stat3 mouse study (26). Thus, to determine the effect of myeloid Stat3 
deletion with regard to this specific strain, we examined the composition of lymphocytes and 
myeloid cells in the knockout mice. Lack of STAT3 in the myeloid lineage did not affect the 
composition of major cell populations in the spleen. Specifically, the percentage of B cells, T 
cells, neutrophils, monocytes, red pulp macrophages (RpMΦ), marginal metallophilic 
macrophages (MMMΦ), and marginal zone macrophages (MZMΦ) in the spleen were similar 
between wild-type and knockout mice (Table 2.1). In the bone marrow, Stat3 knockout mice had 
more SSChi granulocytes and CD11b+ myeloid cells owing to a significant expansion of CD11b+ 
Ly6G+ neutrophils within the granulocyte compartment (Table 2.2). An increase of the CD11b+ 
Ly6Chi monocytes was also observed (Table 2.2). The expansion of neutrophils was 
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accompanied by a mild decrease in B cell and T cell populations in the bone marrow. 
Neutrophilia has been reported by other groups using hematopoietic-specific or inducible Stat3 
knockout mice (28,29). Our results suggest that myeloid-specific deletion of Stat3 is sufficient to 
cause the neutrophil expansion phenotype. The number of CD11blo F4/80+ macrophages in the 
bone marrow did not differ between wild-type and knockout mice (Table 2.2). Similar to the 
previous study (26), we did not observe a differentiation block of STAT3-null BMMs cultured in 
vitro (data not shown), suggesting that STAT3 is not crucial in normal macrophage 
differentiation. Taken together, our data agreed with the previous studies and independently 
verified that myeloid Stat3 deletion leads to neutrophil expansion in the bone marrow but has 
minimal effects on splenic cells or BMM differentiation by using a different Stat3fl/fl strain. 
 
2.3.2  Stat3 knockout BMMs show attenuated type I interferon response to HSV-1 infection 
HSV-1 is able to enter and infect BMMs and peritoneal macrophages, but few infectious 
viral particles are produced following virus entry, indicating that macrophages are non-
permissive to productive HSV-1 infection (4,5). To determine if STAT3 plays a role in the 
intrinsic resistance of macrophages to HSV-1, BMMs from wild-type or knockout mice were 
infected with HSV-1 at a multiplicity of infection (MOI) of 3, and infectious viral particles in the 
supernatant were measured at 12 and 24 hours post infection (hpi) by plaque assay. Similar to 
wild-type BMMs, STAT3 knockout BMMs produced limited amount of infectious viral 
particles, and the viral titer reduced over time (Figure 2.1A), indicating that knockout BMMs are 
capable of restricting HSV-1 replication. No statistical difference was observed between wild-
type and knockout BMMs in their susceptibility to HSV-1 as measured by infectious viral 
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particles produced (Figure 2.1A). Thus, Stat3 deletion in the macrophages does not impair their 
intrinsic resistance to HSV-1. 
To further investigate the response of BMMs to HSV-1, we examined the signaling 
events and host gene expression following HSV-1 infection. HSV-1 induced robust tyrosine 
phosphorylation and activation of STAT1 and STAT3 in wild-type BMMs, and STAT1 
activation appeared to be normal in the absence of STAT3 (Figure 2.1B). Phosphorylation of 
IκBα (p-IκBα) was induced, and phospho-p65 (p-p65) was induced to a lesser extent, indicating 
activation of the NF-κB pathway by HSV-1 infection (Figure 2.1B). Importantly, p-IκBα level 
was higher in knockout BMMs, indicating enhanced NF-κB activity, while the induction of 
ISG15, an interferon-stimulated gene (ISG), was reduced in knockout BMMs (Figure 2.1B). 
HSV-1 also induced the expression of several genes involved in signaling and immune 
regulation (Figure 2.1C-M). Of note, induction of SOCS3, a STAT3 inhibitor highly upregulated 
by active STAT3 (32), was blunted in knockout macrophages (Figure 2.1C), confirming the lack 
of STAT3 functionality in knockout BMMs.  
It has been reported that STAT3-null macrophages express higher levels of pro-
inflammatory genes in response to LPS and bacterial infection (26,30). Similarly, we found that 
during HSV-1 infection, knockout BMMs expressed more TNFα, inducible nitric oxide synthase 
(iNOS), and IL-12b than wild-type BMMs (Figure 2.1D-F), but not other inflammatory 
cytokines such as IL-1β and IL-6 (Figure 2.1G-H). Knockout BMMs also expressed more 
CXCL2 (Figure 2.1I), a neutrophil chemoattractant responsible for neutrophil mobilization to the 
site of HSV-1 infection (33). On the contrary, induction of CCL2, a monocyte chemoattractant 
and a STAT3 target gene, was decreased in knockout BMMs (Figure 2.1J). These data show that 
Stat3 knockout BMMs induce higher expression of a subset of pro-inflammatory cytokines upon 
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viral infection. We also examined the expression of type I interferons and ISGs. While 
expression of IFNβ was unaffected (Figure 2.1K), HSV-1-induced IFNα expression was severely 
diminished in the absence of STAT3 (Figure 2.1L). Moreover, expression of two ISGs, namely 
ISG15 and USP18, was decreased in the knockout BMMs (Figure 2.1B, 2.1M), indicating that 
while STAT3 is dispensable for IFNβ expression, it is required for IFNα expression and optimal 
expression of ISGs in response to HSV-1 infection. 
Taken together, our data showed that in vitro HSV-1 infection activates STAT1 and 
STAT3 in BMMs. Loss of STAT3 did not impair STAT1 activation or the intrinsic ability of 
BMMs to limit HSV-1 replication. However, Stat3 knockout BMMs had significantly lower 
expression of IFNα and ISGs, suggesting that effective induction of IFNα and ISGs in BMMs 
during HSV-1 infection is dependent on STAT3. 
 
2.3.3  Myeloid Stat3 knockout mice are more susceptible to HSV-1 infection 
Type I interferons, including IFNα and IFNβ, are critical in mounting antiviral defense at 
the early stage of viral infection by inducing the expression of ISGs (34). The attenuated type I 
interferon response in STAT3 knockout macrophages may have profound effects on the outcome 
of systemic HSV-1 infection. Thus, we set out to investigate if Stat3 knockout mice are more 
susceptible to systemic HSV-1 infection. Wild-type or knockout mice were infected with 2x108 
pfu of HSV-1 via tail vein injection. Most mice succumbed to death within two days, but the 
wild-type mice survived longer (Figure 2.2A). Viral loads, as determined by HSV-1 genome 
copy number relative to mouse β-Actin copy number, showed a trend of increase in the brain, 
liver, and spleen of knockout mice, but the difference was not statistical significant 
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(Supplemental Figure 2.2). These results suggest that STAT3 in myeloid cells have a protective 
role during lethal systemic HSV-1 infections and prompted further investigation. 
Next, we challenged the mice with a lower dose of HSV-1. Mice were infected with 
1x107 pfu of HSV-1 by tail vein injection. Both groups of mice displayed symptoms including 
hunched posture, signs of hind limb weakness, and significant weight loss starting at 2 days post 
infection (dpi). No statistical difference in survival was observed (Figure 2.2B). However, Stat3 
knockout mice experienced significantly worse weight loss over the course of infection (Figure 
2.2C). To determine the impact of myeloid-specific Stat3 deletion on the innate immunity 
against HSV-1 at the early stage of infection, we examined the viral loads in the brain and the 
spleen at 2 dpi. Stat3 knockout mice had significantly higher viral loads in the brain at 2 dpi 
(Figure 2.2D). Viral loads were also marginally higher in the spleens of knockout mice at 2 dpi 
(Figure 2.2E). These data showed that Stat3 knockout mice are more susceptible to HSV-1 
infection, and the differences are discernible at the earlier stages of infection. 
 
2.3.4  Susceptibility of Stat3 knockout mice is not caused by immunopathology in the brain 
To investigate the mechanisms contributing to the higher brain viral loads in knockout 
mice, we examined the expression of immunoregulatory genes in the brain. Factors including 
IFNα, IFNβ, IFNγ, IL-12, TNFα, and NO are known to be critical in inhibiting HSV-1 
replication in various settings in vitro and in vivo (10-13,35,36). While IFNγ expression in the 
brain was below the detection threshold (data not shown), iNOS, TNFα, IFNα, IFNβ, and IL-12 
were not differentially expressed in the brains of wild-type and knockout mice (Figure 2.3A-E), 
and thus cannot account for the higher viral loads in the brains of STAT3 knockout mice. 
Microglia, a macrophage-like cell type in the brain, are intrinsically resistant to HSV-1 infection 
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(37) and elicit significant immune responses in the brain during HSV-1 infection (23,38,39). 
Given that LysM-Cre has been reported to result in partial deletion of the loxP-flanked gene in 
microglia (40), it is possible that LysM-Cre causes Stat3 deletion in microglia, thereby altering 
their responses to HSV-1 infection and undermining their ability of restricting HSV-1 replication 
in the brain. However, we found that wild-type microglia expressed low levels of STAT3, and 
the expression was not noticeably reduced in the microglia of Stat3 knockout animals (Figure 
3F). Previous studies also suggested that immune cell infiltrates are the major cause of herpes 
simplex encephalitis (HSE) immunopathology (23,41). In this setting, CCL2 and CXCL2 
produced by microglia are the primary macrophage and neutrophil chemoattractants (38,42). To 
probe the possibility of immunopathology in STAT3 knockout mice, we further examined the 
expression of CCL2 and CXCL2. We found that CCL2 and CXCL2 were not differentially 
expressed between wild-type and knockout mice (Figure 3G-3H). Moreover, there was no 
evidence of CD45+ hematopoietic-origin infiltrating cells or Ly6G+ neutrophils in the brains of 
both wild-type and knockout mice (Figure 2.3F). Taken together, our data showed that the higher 
viral loads in the brain and exaggerated symptoms of Stat3 knockout mice are not due to immune 
cell infiltration or microglia defects in the brain. Rather, it is more likely caused by failure of the 
immune system in Stat3 knockout mice to restrain the replication and spread of HSV-1 to the 
central nervous system. 
 
2.3.5  Stat3 knockout mice express reduced levels of antiviral cytokines in the spleen 
Next, we examine the immune responses in the spleens of infected mice. Intravenous 
infection of HSV-1 in mice is known to elicit robust immune responses in the spleen, and splenic 
MMMΦs and MZMΦs are the major producer of type I interferons in this setting (14). Myeloid 
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STAT3 deletion did not affect the percentage of MMMΦ and MZMΦ in the spleen (Table 2.1). 
However, similar to the findings with STAT3 knockout BMMs (Figure 2.1), splenic expression 
of IFNα and USP18 at 2 dpi was significantly lower in the knockout mice, while expression of 
IFNβ and IFNγ was unaffected (Figure 2.4A-D), indicating a partially defective type I interferon 
response. On the contrary, splenic expression of iNOS was not affected by myeloid STAT3 
deletion (Figure 4E), and splenic expression of TNFα and IL-12β was lower in knockout mice 
(Figure 2.4F-G). These data showed that type I interferon response in the spleens of STAT3 
knockout mice is also impaired during systemic HSV-1 infection, while expression of type II 
interferon, namely IFNγ, is not dependent on STAT3. Because TNFα signaling is important in 
promoting DC survival during differentiation and upon activation (43), and DC is a major 
producer of IL-12 in the spleen (44-46), reduced expression of TNFα and IL-12 in Stat3 
knockout mice prompted us to investigate the possibility of defective DC functionality in the 
knockout mice during HSV-1 infection. 
 
2.3.6  Stat3 knockout mice have decreased CD8+ cDC frequency during HSV-1 infection 
STAT3 is critical for DC differentiation from hematopoietic stem cells (47), and it has 
been reported that LysM-Cre can lead to partial deletion of target genes in a small fraction of 
splenic DCs (31). Therefore, we asked if LysM-Cre-mediated Stat3 deletion affects splenic DC 
at steady-state and during HSV-1 infection. We found that myeloid STAT3 deletion did not 
affect the percentage of total splenic DC or CD11b+ conventional DC (cDC) subset at steady-
state. Additionally, knockout mice were able to expand the total splenic DC and CD11b+ cDC 
population to a level comparable to that of wild-type mice in response to HSV-1 infection 
(Figure 2.5A-C). Wild-type and knockout mice also had similar numbers of CD8+ cDCs at 
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steady-state. However, a mild reduction in CD8+ cDC population was observed in the knockout 
mice during HSV-1 infection (Figure 2.5D). Knockout mice also had more steady-state pDCs, 
although similar levels of pDC were observed in wild-type and knockout mice during HSV-1 
infection (Figure 2.5E). These data suggest that STAT3 may have a minor role in pDC 
differentiation at steady-state. Importantly, the reduction of CD8+ cDC population in Stat3 
knockout mice during HSV-1 infection demonstrates that STAT3 contributes to CD8+ cDC 
differentiation, proliferation, or survival in response to HSV-1 infection. 
 
2.3.7  Stat3 knockout mice have impaired NK and T cell activation during HSV-1 infection 
Splenic CD8+ cDCs are specialized to cross-present viral antigens to CD8 T cells to elicit 
virus-specific CTL immunity (20,48). During HSV-1 infection, DCs also have a critical role in 
promoting natural killer (NK) cell and CTL activation (15). Given that Stat3 knockout mice 
failed to expand CD8+ cDC population during HSV-1 infection, we asked if activation of NK 
and CD8+ T cells in Stat3 knockout mice was affected. We found that mock-infected the 
knockout mice had less steady-state splenic NK cells (identified as CD3- NK1.1+), but HSV-1 
infection increased the number of NK cells to a level comparable to that of wild-type mice 
(Figure 2.6A-B). NK cells in wild-type mice upregulated the activation marker CD69 at 2 dpi 
(Figure 2.6C). However, NK cell activation was diminished in Stat3 knockout mice (Figure 6C). 
Activation of CD8 T cells was mostly unaffected by Stat3 deletion (Figure 2.6D), although the 
degree of activation was marginally lower in knockout mice (Figure 2.6E). These data 
demonstrated that myeloid Stat3 deletion leads to impaired NK cell activation and minor defects 
in CD8 T cell activation, and both may contribute to HSV-1 susceptibility of STAT3 knockout 
mice. 
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2.4  Discussion 
In this study, we investigated the role of STAT3 in myeloid cells during HSV-1 infection. 
In vivo, Stat3 knockout mice were more susceptible to HSV-1, as marked by shortened survival, 
higher viral loads in the brain and the spleen, and significant weight loss (Figure 2.2). Myeloid 
Stat3 knockout mice are predisposed to develop chronic colitis at later ages (26), and this may 
complicate our interpretation of the significant weight loss in Stat3 knockout mice. In agreement 
with the previous study, we found that knockout mice usually do not manifest symptoms of 
colitis until 16 weeks old or later. Using healthy mice at around 10 weeks old allowed us to 
avoid mice with pre-existing conditions, although we cannot rule out the possibility of HSV-1 
infection triggering the onset of colitis and impeding the weight gain and recovery from acute 
HSV-1 infection. However, the fact that Stat3 knockout mice also had significantly higher viral 
loads argues that the weight loss is associated with an aggravated disease resulting from impaired 
immune system that fails to restrain the virus from replicating and spreading. 
Viral infections induce the production of type I interferons, namely IFNα and IFNβ. Type 
I interferons promote the expression of ISGs to establish an antiviral state by activating the 
transcription factors STAT1 and interferon-stimulated gene factor 3 (ISGF3), which is comprised 
of STAT1, STAT2, and interferon regulatory factor 9 (IRF9) (34). It has been shown that STAT3 
negatively regulates type I interferon-induced ISGs by inhibiting STAT1 (49,50). Surprisingly, 
our data showed that STAT3 is required for optimal IFNα and ISG expression in the BMMs 
during HSV-1 infection (Figure 2.1B, 2.1L-M). While it is possible that STAT3 directly 
regulates the expression of ISGs in a positive manner during HSV-1 infection, it is more likely 
that reduced expression of ISGs is a result of diminished expression of IFNα. Type I interferon 
production usually occurs in two phases. In the first phase, viral infection activates IRF3 to 
  42 
promote IFNβ expression. In the second phase, IFNβ induces the expression of IRF7, which in 
turn promotes IFNα expression and sustains IFNβ expression (34). We speculate that STAT3 
primarily affects the second phase of interferon production, such as the activation of IRF7, since 
the production of IFNβ was normal in Stat3 knockout BMMs (Figure 2.1K). Additionally, HSV-
1-induced production of type I interferons is mediated by several different cellular sensing 
mechanisms (45,51-53). It is also possible that these sensing mechanisms are impaired in the 
absence of STAT3, resulting in diminished IFNα production. Apart from the impaired type I 
interferon response, Stat3 knockout BMMs also highly express a subset of pro-inflammatory 
genes upon HSV-1 infection (Figure 2.1D-F). It has been shown that Stat3 knockout BMMs have 
prolonged and heightened inflammatory response due to defective IL-10 signaling (26). Elevated 
expression of pro-inflammatory genes in Stat3 knockout BMMs is presumably driven by hyper-
activation of NF-κB. It has been shown that STAT3 keeps the activity of NF-κB in check by 
inhibiting the expression of a positive regulator of NF-κB (54) and by promoting the expression 
of a microRNA that suppresses NF-κB (55). Our data corroborated with previous studies by 
showing that the phosphorylation of IκBα and the expression of the classic NF-κB target gene 
TNFα were significantly increased in Stat3 knockout BMMs (Figure 2.1B, 2.1D), suggesting an 
elevated NF-κB activity. 
During systemic infection of HSV-1, Stat3 knockout mice expressed less IFNα, IL-12 
and TNFα in the spleen (Figure 2.4A, 2.4F-G). The antiviral effect of IFNα is well established 
(36). TNFα also inhibits HSV-1 replication in vitro (9). In vivo, TNFα protects mice from lethal 
herpes encephalitis (12), and IL-12 promotes the protective Th1 response against herpesvirus 
(11). Thus, dampened expression of IFNα, IL-12, and TNFα in the spleen may collectively 
contribute to the susceptibility of STAT3 knockout mice. The source of these cytokines, 
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however, remains to be determined. It has been shown that MMMΦ and MZMΦ are the major 
source of IFNα in the spleen during HSV-1 infection (14), and pDC, cDC, and other cell types 
are also capable of producing ample amount of IFNα when exposed to HSV-1 (45,51). Reduced 
expression of IL-12 in knockout mice may be due to reduced CD8+ cDC population during HSV-
1 infection, since CD8+ cDCs are efficient IL-12 producers (44). 
The role of neutrophils in viral infections ranges from protective to immunopathological 
(56). Early studies using Gr-1 antibody for neutrophil depletion suggested that infiltrating 
neutrophils suppress HSV-1 replication in cornea (21). However, Gr-1 is expressed by other 
groups of immune cells, and it was later revealed that non-neutrophil Gr-1+ cells are primarily 
responsible for HSV-1 inhibition (57). Moreover, infiltrating neutrophils are a major mediator of 
HSV-1-induced immunopathology in the brain and the cornea (22,23), and CXCL2 promotes 
neutrophil chemotaxis to the site of infection during HSV-1 infection (58). Given that myeloid 
Stat3 knockout mice have a significant expansion in neutrophil population, we originally 
speculated that increased neutrophil infiltration in the brain leads to aggravated symptoms. 
Nonetheless, both wild-type and Stat3 knockout mice were devoid of Ly6G+ neutrophil or 
CD45+ hematopoietic cell infiltrates in the brain (Figure 2.3F), and CXCL2 expression level was 
indistinguishable between wild-type and knockout mice (Figure 2.3H), indicating that 
neutrophil-mediated immunopathology is not implicated in the susceptibility of Stat3 knockout 
mice to HSV-1. The role of neutrophils in the spleen and the blood during systemic HSV-1 
infection will require further investigation. 
The effect of myeloid STAT3 knockout on DC differentiation (Figure 2.5) is minimal 
comparing to hematopoietic STAT3 knockout, which results in a drastic reduction in DC 
population (47). The majority of splenic DCs are from common myeloid progenitors (CMPs) 
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(59,60). Given that LysM-Cre is only moderately expressed in CMPs (61), the minor impacts of 
myeloid STAT3 deletion on DC differentiation can be explained by an incomplete deletion of 
STAT3 in CMPs. The reason for increased steady-state pDC population in our model is unclear. 
In fact, CD11c-Cre-mediated STAT3 knockout causes a reduction in pDC population (62). It has 
been shown that the immediate DC progenitors express high level of STAT3 but are CD11c 
negative, and they upregulate CD11c just prior to differentiating into distinct DC subsets (63). 
Thus, CD11c-Cre-mediated Stat3 deletion would have occurred at the final stage of DC 
differentiation. In order to understand how STAT3 affects pDC differentiation, it will be of 
interest to compare how LysM-Cre and CD11c-Cre affect STAT3 expression in these immediate 
DC progenitors and the consequences of such perturbations. On the other hand, myeloid Stat3 
knockout mice have a reduction in CD8+ cDC population during HSV-1 infection. It is possible 
that STAT3 facilitates the differentiation or proliferation of CD8+ cDC in response to acute 
HSV-1 infection. However, given that myeloid STAT3 knockout does not affect the 
differentiation of steady-state CD8+ cDCs, we speculate that STAT3 regulates the survival of 
CD8+ cDCs during HSV-1 infection. Activated DCs are known to undergo apoptosis unless 
protected by TNFα (43) and HSV-1 also induces apoptosis in infected DCs (64). The reduction 
of splenic CD8+ cDCs in Stat3 knockout mice during HSV-1 infection is likely a result of 
reduced splenic TNFα and enhanced apoptosis. 
DCs play a critical role in controlling HSV-1 pathogenesis by mediating NK and T cell 
activation, and mice depleted of DCs show higher mortality and higher viral loads in the nervous 
system (15). CD8+ cDCs are unique in their ability to cross present viral antigens to CD8 T cells 
and promote CTL response against HSV-1 infection (20,48). We found that activation of NK 
cells was dampened in STAT3 knockout mice (Figure 2.6C). Impaired activation of NK cells 
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may be due to the combinatory effect of reduced CD8+ cDCs and diminished IL-12 and IFNα 
expression, since IL-12 secreted by CD8+ cDCs and IFNα both mediate NK cell activation 
during viral infection (18,65). Because we did not observe a difference in NK cytotoxicity in 
vitro (data not shown), it will be of interest to determine if NK cells from Stat3 knockout mice 
are deficient in other aspects, such as cytokine production. We also noticed a minor decrease in 
CD8 T cell activation altitude at 2 dpi (Figure 2.6E). Whether this observation translates to 
compromised adaptive immunity to HSV-1 at the later stage of infection awaits further 
investigation. Interestingly, knockout mice also showed a moderate reduction in the steady-state 
NK cell population (Figure 2.6B). It is unclear why myeloid Stat3 deletion leads to reduction of 
NK cells, since NK cells are generally believed to arise from the lymphoid lineage (66). 
However, it has been recently reported that myeloid precursors are capable of differentiating into 
NK cells (67,68), thereby raising possible implications of myeloid STAT3 in NK cell 
development. 
In conclusion, our data showed that myeloid-specific Stat3 deletion causes defects in 
multiple aspects of the innate immune system in response to HSV-1. While individual defects 
may not change the outcome of infection, collectively they result in higher susceptibility of Stat3 
knockout mice to HSV-1. Future studies will be focusing on the mechanisms with respect to each 
defect, such as the mechanism by which STAT3 modulates IFNα production. The impact of 
impaired innate immunity on adaptive immunity-mediated control of HSV-1 infection and 
reactivation will be another interesting area for investigation. 
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2.5  Materials and Methods 
Animals. This study was performed under protocols approved by Institutional Animal 
Care and Use Committee guidelines of the University of North Carolina Chapel Hill. Mice were 
kept and bred in sterile facilities under conditions in accordance with NIH Guide for the Care 
and Use of Laboratory Animals and UNC IACUC guidelines. Stat3fl/fl and LysM-Cre C57BL/6 
mice were obtained from the Jackson laboratory. Mice were bred to each other to generate 
myeloid-specific STAT3 knockout mice. Eight to 12-week old animals were used for HSV-1 
infection studies. For infections, mice were intravenously injected via the tail vein with HSV-1 
(KOS strain) and monitored one to three times daily after injection. To collect tissues for 
molecular studies, mice were euthanized by CO2 followed by cervical dislocation. For survival 
studies, mice lost more than 20% of original weight were immediately euthanized, while all other 
mice were euthanized at the end of the study. 
Virus, cells, and plaque assay. Vero cells (ATCC) were propagated in DMEM with 
10% FBS. HSV-1 (KOS strain) was amplified on Vero cells. Three days post-infection, 
supernatants were harvested and centrifuged at 2500 rpm to remove cell debris. The supernatants 
were then ultracentrifuged at 25,000 rpm to concentrate the virus. Virus pellets were resuspended 
in plain DMEM. To isolate bone marrow-derived macrophages (BMMs), bone marrows were 
collected from the femur and tibia of age- and sex-matched 8-10 weeks old mice. The cells were 
cultured in RPMI 1640 with 10% FBS and 10% L929-conditioned media. After 5-6 days of 
culture, the adherent cells contained about 95% F4/80-positive macrophages as determined by 
flow cytometry. BMMs were infected with HSV-1 at a multiplicity of infection (MOI) = 3, 
incubated at 37°C for 30 min, washed with DMEM twice, and cultured in DMEM with 2% FBS. 
Infectious viral titer was determined by plaque assay using Vero cells. Supernatants from 
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infected macrophages were serial-diluted in DMEM before infecting confluent Vero cells for 1 
hour at 37°C, after which the supernatants were replaced with DMEM with 1% of 
methylcellulose and 2% of serum. Three technical replicates were prepared for each dilution. 
Infected Vero cells were kept at 37°C with 5% CO2 for 72 hours before staining with 0.5% 
crystal violet in 50% ethanol to reveal the plaques. Titers were shown as plaque-forming unit 
(pfu) per ml. 
Quantitative real-time PCR. Total RNA from the cultured macrophages or mouse 
tissues were purified using QIAGEN RNeasy Plus kit according to manufacturer’s protocol. One 
to 2 µg of RNA was used to synthesize cDNA using M-MLV reverse transcriptase (Life 
Technologies, Carlsbad, CA, USA). For gene expression assay, standard TaqMan probes, 
primers, and reagents were used (Thermo Fisher, Walthem, MA, USA). To determine the 
relative genomic copy number of HSV-1 in mouse tissues, real-time PCR was performed using 
Maxima SYBR green master mix (Thermo Fisher) with the following primers: Actb forward: 5’-
GGCTGTATTCCCCTCCATCG-3’; Actb reverse: 5’-CCAGTTGGTAACAATGCCATGT-3’; 
HSV-1 pol forward: 5’-CATCACCGACCCGGAGAGGGAC-3’; HSV-1 pol reverse: 5’-
GGGCCAGGCGCTTGTTGGTGTA-3’. 
Immunoblotting. Cells or tissues were lysed in RIPA buffer (10 mM Tris pH 8.0, 1 mM 
EDTA, 1 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl) 
with a protease inhibitor cocktail (Promega, Madison, WI, USA) and a phosphatase inhibitor 
cocktail (Sigma, St. Louis, MO, USA). Lysates were centrifuged to remove cell debris, and the 
supernatant were mixed with LDS loading buffer (Life Technologies) containing 100 mM DTT 
and heated before running SDS-PAGE with bis-tris NuPAGE gel and MOPS buffer (Life 
Technologies). Proteins were transferred onto 0.45 µm PVDF membrane, blocked with 5% milk 
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in TBST, and incubated in primary antibodies at the dilution of 1:500 to 1:2000 in 5% milk in 
TBST overnight. Blots were then washed and incubated in the appropriate HRP-conjugated 
secondary antibodies (Promega). Chemiluminescence substrate (Thermo Fisher) was used for 
film exposure. STAT1 (#9172), p-STAT1 (#9167), STAT3 (#9139), p-STAT3 (#9145), ISG15 
(#2758), p-p65 (#3033), p65 (#3034), p-IκBα (#9246), and IκBα (#4812) antibodies were from 
Cell Signaling Technology (Danvers, MA, USA). 
Flow cytometry. Mice were euthanized to collect the spleens and bone marrows. Spleens 
were mashed using syringe plungers and 100 µm cell strainers. The cells were resuspended in 
FACS buffer (3% FBS, 1mM EDTA in PBS), passed through 40 µm cell strainer, and red blood 
cells were lysed by ACK buffer (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA). The white 
blood cell suspensions were blocked with anti-mouse CD16/CD32 antibody (eBioscience14-
0161-86) at 1:100 dilution for 30 minutes before being stained with the appropriate primary and 
secondary antibodies for 1 hour each at 1:100 dilution in FACS buffer. CD8-FITC (11-0081-81), 
CD4-PE (12-0042-81), CD19-PE-Cy7 (250193-81), CD3-APC (17-0032-82), F4/80-Alexa488 
(53-4801-82), CD11b-PE-Cy7 (250112-82), CD11c-APC (17-0114-82), CD209-PE (12-2091-
82), and streptavidin-eF450 (48-4317-82) antibodies were from eBioscience (San Diego, CA, 
USA). Ly6G-PE (108407), Ly6C-APC (128015), B220-biotin (103204), CD169-PE-Cy7 
(142412), CD69-APC (104513), and NK1.1-PE-Cy7 (108713) antibodies were from BioLegend 
(San Diego, CA, USA). Flow cytometry was carried out on a CyAn machine and analyzed by 
FlowJo. 
Immunohistochemistry. Mouse tissues were fixed in 10% buffered formalin for 24 
hours, washed with PBS three times, and incubated in 30%, 50%, and 70% ethanol for 30 
minutes each. Fixed tissues were embedded in paraffin and sectioned into slices. 
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Immunohistochemistry was carried out with Bond immunostainer (Leica Biosystems Inc.  
Norwell, MA). Slides were dewaxed in Bond dewax solution (AR9222) and hydrated in Bond 
wash solution (AR9590). Antigen retrieval was performed for 30 min at 100ºC in Bond-Epitope 
Retrieval solution1 pH-6.0 (AR9961) followed by a 10-minute protein block (#X0909, DAKO, 
Carpineria, CA). Rodent block M reagent (# RB961G, Biocare Medical, Concord, CA) was 
applied for 20 min only to STAT3 slides. After pretreatment, slides were incubated for 30 min 
with CD45 and Ly-6G (Abcam #25386, #25337) antibodies at 1:100 and 1:200 dilution 
respectively, and for 1h with STAT3 (Cell Signaling #9139) antibody at 1:750 dilution. 
Detection of all antibodies was performed using Bond™ Polymer Refine Detection (DS9900), 
and for CD45 and Ly-6G the secondary antibody from the kit was replaced with ImmPRESS 
HRP Anti-Rat Ig (#MP-7444-15, Vector Labs, Burlingame, CA). Stained slides were dehydrated 
and coverslipped. Positive and negative controls (no primary antibody) were also performed for 
each antibody to ensure the specificity of staining. 
Statistical analyses. Three to five technical replicates were used for each data point. 
Data points were shown as mean with standard deviation, and two-tailed Student’s t-test was 
used to calculate p-value and significance unless otherwise noted. 
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Table 2.1  Cellular composition of the spleena 
 WT (n=3) KO (n=3) 
Myeloid cellsb 12.3 ± 4.7 11.8 ± 2.6 
Neutrophilsc (% myeloid) 16.9 ± 5.9 19.6 ± 7.4 
Ly6Chi monocytesd (% myeloid) 28.7 ± 2.0 32.6 ± 10.5 
Ly6Clo monocytese (% myeloid) 51.9 ± 7.6 45.3 ± 17.9 
Red pulp macrophagesf 2.42 ± 0.40 2.77 ± 0.12 
Marginal zone macrophagesg 0.24 ± 0.03 0.28 ± 0.08 
Marginal metallophilic macrophagesh 0.40 ± 0.11 0.51± 0.18 
B cellsi 56.7 ± 4.2 51.6 ± 3.2 
T cellsj 26.4 ± 1.0 27.4 ± 5.7 
CD4+ T cellsk (% T cells) 50.6 ± 3.5 52.7 ± 3.4 
CD8+ T cellsl (% T cells) 41.3 ± 1.7 39.0 ± 1.7 
a All numbers are expressed as percent of total cells except where noted. 
b CD11b+ 
c CD11b+ Ly6G+ Ly6C+  
d CD11b+ Ly6G- Ly6C+  
e CD11b+ Ly6G- Ly6Clo 
f CD11blo F4/80+ 
g CD11c- CD209+ 
h CD11c- CD169+ 
i CD19+ 
j CD3+ 
k CD3+ CD4+ 
l CD3+ CD8+ 
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Table 2.2  Cellular composition of the bone marrowa. 
 WT (n=3) KO (n=2) 
Granulocytesb 54.8 ± 1.2 68.2 ± 4.5 * 
Myeloid cellsc 45.7 ± 0.8 58.9 ± 6.2 * 
Neutrophilsd 27.9 ± 0.3 40.4 ± 5.0 * 
Neutrophils (% Myeloid cells) 61.3 ± 1.2 68.6 ± 1.3 ** 
Macrophagese 1.3 ± 0.2 1.1 ± 0.5 
Ly6Chi monocytesf 5.3 ± 0.4 6.4 ± 0.3 * 
Ly6Clo monocytesg 10.2 ± 0.8 10.2 ± 0.9 
a All numbers are expressed as percent of total cells except where noted. 
b SSChi 
c CD11b+ 
d CD11b+ Ly6G+ Ly6C+  
e CD11blo F4/80+ 
f CD11b+ Ly6G- Ly6Chi 
g CD11b+ Ly6G- Ly6Clo 
*p<0.05; **p<0.01 
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Figure 2.1  STAT3 knockout BMMs show attenuated type I interferon response to HSV-1 
infection 
WT or STAT3 KO BMMs were infected with HSV-1 at MOI=3. (A) Viral titer in the 
supernatants at 12 and 24 hpi was determined by plaque assay on Vero cells with three technical 
replicates. (B) Western blotting of lysates from HSV-1 infected BMMs at the indicated time-
points. (C-M) Gene expression of HSV-1 infected BMMs was determined by qRT-PCR with 
three technical replicates for each sample. All values were normalized to Gusb and compared to 
the expression of WT BMMs at 0h except for IFNα, which was shown as relative expression to 
Gusb. All values were shown as mean with 95% confidence intervals. Statistical significance 
was determined by Student’s t-test. *p<0.05. **p<0.01. N.d.= not determined (below detection 
threshold).  
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Figure 2.2  Myeloid STAT3 knockout mice are more susceptible to HSV-1 infection 
(A) Five sex- and age-matched WT or KO mice were intravenously injected with 2x108 pfu of 
HSV-1. Survival of infected mice was monitored three times daily. Statistical analysis was done 
by log-rank test. (B) Ten sex- and age-matched WT or KO mice were intravenously injected with 
1x107 pfu of HSV-1. Survival of infected mice was monitored and analyzed as described in (A). 
(C) Sex- and age-matched WT or KO mice were intravenously injected with 1x107 pfu of HSV-
1. Each mouse was weighted immediately before infection and twice daily after infection. All 
measurements were normalized to the starting weight of each mouse and expressed as a 
percentage of the starting weight. Statistical analysis was done by repeated measurement 
ANOVA using PRISM (GraphPad). (D-E) Five mice of each genotype were infected as 
described in (C) and sacrificed at 2 dpi. HSV-1 viral loads in the brain or the spleen were 
determined by qRT-PCR with three technical replicates for each mouse. Data were shown as 
HSV-1 copy number relative to mouse Actb expression. Statistical significance was determined 
by Student’s t-test. **p<0.01 
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Figure 2.3  Susceptibility of STAT3 knockout mice is not caused by immunopathology in 
the brain 
WT or KO mice were intravenously injected with 1x107 pfu of HSV-1 as described in Figure 3. 
Five mice of each genotype were sacrificed at 2 dpi to collect the brains. (A-E) Relative 
expression of iNOS, TNFα, IFNα, IFNβ, IL-12 in the brain was determined by qRT-PCR with 
three technical replicates for each mouse. All values were normalized to Gusb expression and 
shown as mean with 95% confidence intervals. Statistical analysis was done by Student’s t-test. 
N.s. = not significant (F) Brain hemispheres from WT or KO mice sacrificed at 2 dpi were fixed 
and stained with STAT3, CD45, or Ly6G antibodies as described in Materials and Methods. 
Microglia showed low levels of CD45 staining. Representative figures from each genotype were 
shown. (G-H) Relative expression of CCL2 and CXCL2 in the brain was determined by qRT-
PCR as mentioned above.  
WT KO
STAT3
CD45
Ly6G
FIGURE 3
WT KO
0.0
0.1
0.2
0.3
0.4
Nos2
R
el
at
iv
e 
ex
pr
es
si
on
 to
 G
us
b n.s.
WT KO
0.00
0.05
0.10
0.15
Il12b
R
el
at
iv
e 
ex
pr
es
si
on
 to
 G
us
b n.s.
WT KO
0.00
0.05
0.10
0.15
R
el
at
iv
e 
ex
pr
es
si
on
 to
 G
us
b
Ccl2
n.s.
WT KO
0.000
0.002
0.004
0.006
0.008
Cxcl2
R
el
at
iv
e 
qu
an
tit
y 
to
 G
us
b n.s.
WT KO
0.00
0.02
0.04
0.06
0.08
0.10
Tnf
R
el
at
iv
e 
ex
pr
es
si
on
 to
 G
us
b n.s.
WT KO
-2
0
2
4
6
Ifna2
R
el
at
iv
e 
ex
pr
es
si
on
 to
 G
us
b n.s.
WT KO
-2
0
2
4
6
Ifnb1
R
el
at
iv
e 
ex
pr
es
si
on
 to
 G
us
b n.s.
A B C D
E
F
G
H
  55 
 
Figure 2.4  STAT3 knockout mice express reduced levels of antiviral cytokines in the spleen 
WT or KO mice were infected as described in Figure 3. Five mice of each genotype were 
sacrificed at 2 dpi to collect the spleens. (A-H) Expression of IFNα, USP18, IFNβ, IFNγ, iNOS, 
TNFα, and IL-12 in the spleen was determined by qRT-PCR with three technical replicates for 
each mouse. All values were normalized to Gusb expression and shown as mean with 95% 
confidence intervals. Statistical analysis was done by t-test. **p<0.01. *p<0.05. N.s. = not 
significant. 
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Figure 2.5  STAT3 knockout mice have decreased CD8+ cDC frequency during HSV-1 
infection 
Sex- and age-mached WT or KO mice were infected with 1x107 pfu of HSV-1 by tail vein 
injection. Mock-infected WT (N=3) and KO mice (N=3), and infected WT (N=5) and KO mice 
(N=4) were sacrificed at 2 dpi, and splenic cells were collect for flow cytometry analysis. (A) 
Splenic cells were gated on CD11c+ followed by CD8, CD11b, and B220 analyses to determine 
the percentage of CD8+ cDC (CD11c+ CD8+ CD11b-), CD11b+ cDC (CD11c+ CD8- CD11b+), 
and pDC (CD11c+ CD8- CD11b- B220+) populations. Representative figures from one mouse of 
each group were shown here. (B-E) Results summarized the percentage of total DC, CD11b+ 
cDC, CD8+ cDC, and pDC from flow analysis. Data were shown as mean with standard 
deviation. Statistical analysis was done by Student’s t-test. *p<0.05. **p<0.01. 
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Figure 2.6  STAT3 knockout mice have impaired NK and T cell activation during HSV-1 
infection 
WT and KO mice were infected and sacrificed for flow cytometry analysis as described in Figure 
6. (A) Representative figures of one mouse from each group were shown. NK cells in the spleen 
were defined by CD3- NK1.1+ gate. Activated NK cells were further gated by CD69+ staining. 
(B-C) Results summarized the percentage of total NK and activated NK cells. (D) Results 
summarized the percentage of activated CD8 T cells (CD3+ CD8+ CD69+) in the spleen. (E) The 
mean fluorescence intensity (MFI) of CD69 was calculated from activated CD8 T cells defined 
in (D). Data were shown as mean with standard deviation. Statistical analysis was done by 
Student’s t-test. * p<0.05. **p<0.01.  
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Supplemental Figure 2.1  Myeloid-specific deletion of STAT3 
Tissues from WT and KO mice were homogenized in RIPA buffer, while BMMs were lysed in 
RIPA buffer. The lysates were subjected to western blotting to determine the levels of STAT3 
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in Materials and Methods to determine the levels of STAT3.
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Supplemental Figure 2.2  KO mice showed marginally higher viral loads in the brain 
Five sex- and age-matched WT and KO mice were intravenously injected with 2x108 pfu of 
HSV-1. The brains (A), livers (B), and spleencs (C) were collected postmortem to determine 
HSV-1 viral loads by qRT-PCR with three technical replicates per mouse. Data were shown as 
HSV-1 copy number relative to mouse Actb expression. Statistical significance was determined 
by Student’s t-test. 
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Five sex- and age-matched WT or KO mice were intravenously injected with 2x108 pfu of 
HSV-1. The brains (A), livers (B), and spleens (C) were collected postmortem to determine 
HSV-1 viral loads by qRT-PCR with three technical replicates for each mouse. Data were 
shown as HSV-1 copy number relative to mouse Actb expression. Statistical significance 
was determined by Student’s t-test.
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CHAPTER 3: CYTOSOLIC DNA PROMOTES STAT3 PHOSPHORYLATION BY 
TBK1 TO RESTRAIN STAT3 ACTIVITY2 
3.1  Summary 
Cytosolic DNA can elicit beneficial as well as undesirable immune responses. For 
example, viral or microbial DNA triggers cell-intrinsic immune responses to defend against 
infections, whereas aberrant cytosolic accumulation of self-DNA results in pathological 
conditions, such as autoimmunity. Given the importance of these DNA-provoked responses, a 
better understanding of their molecular mechanisms is needed. Cytosolic DNA engages 
stimulator of interferon genes (STING) to activate TANK-binding kinase 1 (TBK1), which 
subsequently phosphorylates the transcription factor interferon regulatory factor 3 (IRF3) to 
promote interferon expression. Recent studies have reported that additional transcription factors, 
including nuclear factor kappa-B (NF-κB) and signal transducer and activator of transcription 6 
(STAT6), are also activated by cytosolic DNA, suggesting that cytosolic DNA-induced gene 
expression is orchestrated by multiple factors. Here we show that cytosolic DNA activates 
STAT3, another member of the STAT family, via an autocrine mechanism involving interferon β 
(IFNβ) and IL-6. Additionally, we observed a novel cytosolic DNA-induced phosphorylation at 
serine 754 in the transactivation domain of STAT3. Upon cytosolic DNA stimulation, S754 is 
directly phosphorylated by TBK1 in a STING-dependent manner. Moreover, S754 
                                                
2 This chapter has been accepted by Journal of Biological Chemistry and is placed in this 
dissertation after additional editing by the author. The original citation is as follows: H-C Hsia, 
JE Hutti, AS Baldwin. Cytosolic DNA Promotes Signal Transducer and Activator of 
Transcription 3 (STAT3) Phosphorylation by TANK-binding kinase 1 (TBK1) to Restrain 
STAT3 Activity. Journal of Biological Chemistry. 2017 Feb 10. (In press) 
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phosphorylation inhibits cytosolic DNA-induced STAT3 transcriptional activity, and selectively 
reduces STAT3 target genes that are upregulated in response to cytosolic DNA. Taken together, 
our results suggest that cytosolic DNA-induced STAT3 activation via IFNβ and IL-6 is 
restrained by S754 phosphorylation of STAT3. Our findings reveal a new signaling axis 
downstream of the cytosolic DNA pathway and suggest potential interactions between innate 
immune responses and STAT3-driven oncogenic pathways. 
 
3.2  Introduction 
Double-stranded DNA (dsDNA) in the cytosol is a danger-associated molecular pattern 
(DAMP) that triggers inflammation and immune responses. Cytosolic DNA can be derived from 
viral or intracellular microbial infections, undigested phagocytosed materials, and activated self 
retroelements (1). The presence of cytosolic DNA is detected by several cellular sensors, which 
in turn initiate signaling cascades to induce inflammatory response and type I interferon 
production (2). Despite the redundancy between these cytosolic DNA sensors, cyclic GMP-AMP 
synthase (cGAS) is the predominant sensor relaying the presence of cytosolic DNA to 
downstream signaling cascades (3). Upon binding to dsDNA, cGAS produces cyclic 2’-3’ GMP-
AMP (cGAMP), which serves as a second messenger to activate the endoplasmic reticulum 
adaptor protein stimulator of interferon genes (STING) (3-6). Activation of STING by cGAMP 
leads to STING oligomerization, followed by recruitment and activation of TANK-binding 
kinase 1 (TBK1) (7,8).  Subsequently, TBK1 phosphorylates interferon regulatory factor 3 
(IRF3) to promote expression of interferons (IFNs), thereby initiating immune responses to 
establish an antiviral state (7,9,10). In addition to IRFs, other transcription factors, including 
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nuclear factor κB (NF-κB) and signal transducer and activator of transcription 6 (STAT6), are 
also activated by STING and TBK1 downstream of cytosolic DNA (11-14).  
The transcription factor STAT3 is activated by tyrosine 705 phosphorylation downstream 
of a variety of cytokines, such as epidermal growth factor (EGF) and IL-6 (15). Phosphorylation 
at tyrosine 705 leads to nuclear accumulation of STAT3 homodimers and expression of target 
genes containing a gamma-activated site (GAS) in their promoters (16). STAT3 drives the 
expression of pro-survival and inflammatory genes, and sustained activation of STAT3 has been 
shown to promote proliferation, enhance survival of neoplastic cells, and facilitate inflammation-
driven tumorigenesis (17-19). In addition to its role in promoting tumorigenesis, STAT3 also 
represses the anti-tumor activity of hematopoietic cells, making it a key candidate for targeted 
cancer therapy and immunotherapy (20,21). STAT1, another STAT family member, 
predominantly functions downstream of interferons. STAT1 homodimers induced by IFNγ 
recognize almost identical GAS sites as STAT3 dimers do in vitro, but STAT1 and STAT3 have 
different, albeit overlapping, target genes in vivo (22). On the other hand, type I IFNs, including 
IFNα and IFNβ, induce the formation of not only STAT1 homodimer but interferon-stimulated 
gene factor 3 (ISGF3) complex comprising of STAT1, STAT2, and IRF9. The ISGF3 complex 
promotes the expression of genes containing an IFN-stimulated response element (ISRE) in their 
promoters (23). Reciprocal antagonizing effects between STAT1 and STAT3 can be observed in 
certain scenarios (24). For example, STAT3 inhibits STAT1-dependent induction of ISRE genes 
in response to type I IFN stimulation presumably through STAT1:STAT3 heterodimerization 
(25). 
While dimerization and activity of STAT proteins are controlled by tyrosine 
phosphorylation, recent studies demonstrated that the function of STATs can also be modulated 
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by TBK1 and the closely related kinase IκB kinase epsilon (IKKε). Phosphorylation of STAT1 at 
S708 by IKKε disrupts STAT1 homodimerization and favors ISGF3 formation, thereby shifting 
the type I IFN-induced gene expression profile from GAS-driven genes to ISRE-driven genes 
(26). Cytosolic nucleic acids and viral infections engage the STING-TBK1 pathway, leading to 
TBK1-mediated phosphorylation of STAT6 at S407 and STAT6 activation (14). Interestingly, 
functional loss of cGAS or STING has been observed in colorectal cancer and melanoma and 
correlates with disease progression and elevated STAT3 activation (27-29), suggesting a role of 
STING in restricting STAT3 activity and tumor progression. Thus, we sought to determine if 
activity of STAT3 can be regulated by the STING-TBK1 pathway downstream of cytosolic 
DNA. Here we show that STAT3 is activated by cytosolic DNA through an autocrine 
mechanism involving IFNβ and IL-6. At the same time, cytosolic DNA activates TBK1 in a 
cGAS and STING dependent manner to directly phosphorylate STAT3 at serine 754 in the 
transactivation domain (TAD). This TBK1-mediated phosphorylation at S754 is inhibitory and 
restrains cytosolic DNA, IL-6, and IFNβ-induced activation of STAT3. Our finding provides a 
possible explanation to the role of STING in limiting STAT3 activation, and further emphasizes 
the complex signaling cascades and gene expression initiated by cytosolic DNA. 
 
3.3  Results 
3.3.1  TBK1 directly phosphorylates STAT3 at serine 754  
Previous studies demonstrated that TBK1 and IKKε, respectively, regulate the function of 
STAT6 and STAT1 by direct phosphorylation (14,26). To determine if TBK1 and IKKε also 
phosphorylate other STATs, we examined the sequences of STATs against the optimal substrate 
motif for TBK1 and IKKε (30,31), and identified serine 754 in the TAD of STAT3 as a potential 
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TBK1/IKKε phosphorylation site (Figure 3.1A). In order to test if STAT3 is a substrate of TBK1 
or IKKε, IKKε and STAT3 were overexpressed in HEK293T cells, and immunoprecipitated 
STAT3 was blotted with an IKK family phospho-substrate motif antibody (see Materials and 
Methods). Overexpression of wild-type IKKε strongly induced phosphorylation of STAT3 at 
Y705 as well as a site recognized by the IKK phospho-substrate motif antibody (Figure 3.1B). 
We then generated an antibody specific for phospho-S754-STAT3 and repeated the experiment 
with TBK1. Similarly, overexpression of wild-type, but not kinase-dead, TBK1 induced STAT3 
phosphorylation at multiple sites, and S754A mutation of STAT3 abolished the signal of pS754-
STAT3 specific antibody (Figure 3.1C), suggesting that TBK1 kinase activity is critical for the 
phosphorylation of STAT3 at S754. Overexpression of TBK1 and IKKε in HEK293T may lead 
to activation of other kinases, which in turn phosphorylate STAT3. To determine if TBK1 is 
capable of phosphorylating STAT3 directly, we performed an in vitro kinase assay with purified 
TBK1 and recombinant GST-STAT3 from bacteria. Autoradiography showed that incubation 
with wild-type but not kinase-dead TBK1 led to strong phosphorylation on wild-type STAT3, 
and that S754A mutation of STAT3 abolished the phosphorylation (Figure 3.1D). This TBK1-
mediated phosphorylation on STAT3 was also recognized by the pS754-STAT3-specific 
antibody (Figure 3.1D). These data show that TBK1 is capable of directly phosphorylating 
STAT3 at S754.  
 
3.3.2  STAT3 is phosphorylated at S754 in response to cytosolic dsDNA 
TBK1 is activated downstream of toll-like receptors (TLRs) and several other TLR-
independent pathways (32). To determine if S754 phosphorylation of STAT3 occurs under these 
conditions, we asked if these TBK1-activating agonists promote STAT3 phosphorylation at 
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S754. L929 cells were treated with lipopolysaccharide (LPS), or transfected with poly(I:C), 
poly(dA:dT), or a 70-bp long double-stranded DNA (VACV70mer) (33), to engage TLR4, 
MDA5/RIG-I, or the cytosolic DNA pathway, respectively. Transfection with poly(I:C) or DNA 
resulted in varying degrees of TBK1, IRF3, and STAT1 activation, but only transfection with 
dsDNA, including poly(dA:dT) and VACV70mer, led to strong phosphorylation of STAT3 at 
S754 (Figure 3.2A). Induction of STAT3 S754 phosphorylation correlated with robust TBK1 
activation (as marked by S172 phosphorylation) and phosphorylation of IRF3, a major substrate 
of TBK1 (Figure 3.2A). STAT3 was also activated by cytosolic dsDNA transfection, as marked 
by Y705 phosphorylation, which was accompanied by a modest induction of S727 
phosphorylation (Figure 3.2A). This demonstrates that cytosolic dsDNA leads to TBK1 
activation, STAT3 activation, and S754 phosphorylation of STAT3. To determine if similar 
responses can be observed in human cell lines, we tested the human monocytic cell line THP-1 
with these stimuli as well as flagellin, which signals through TLR5. Similarly, cytosolic DNA, 
especially poly(dA:dT), induced the most robust S754 and Y705 phosphorylation of STAT3. 
This was accompanied by slight STAT3 S727 phosphorylation and robust activation of STAT1 
(Figure 3.2B). Poly(dA:dT) transfection induced association of STAT3 with TBK1 and IKKε, 
while VACV70mer induced association of STAT3 with TBK1 but not IKKε (Figure 3.2B). 
These stimuli also induced various degrees of IKKα/IKKβ activation and p65 phosphorylation, 
indicative of NF-κB activation (Figure 3.2B). Finally, a time-course experiment revealed that 
association between TBK1 and STAT3 was induced as early as 1.5 hours after dsDNA 
transfection, coinciding with the timing of S754 phosphorylation, while Y705 phosphorylation of 
STAT3 was detected at a later time-point (Figure 3.2C). Taken together, these data show that 
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among different TBK1 activators, cytosolic DNA induces the most robust STAT3 activation and 
phosphorylation at S754. 
 
3.3.3  TBK1 is required for cytosolic DNA-induced STAT3 phosphorylation at S754 
Given that cytosolic DNA induces robust TBK1 activation, STAT3 phosphorylation, and 
association between TBK1 and STAT3, we asked if TBK1 is required for cytosolic DNA-
induced S754 phosphorylation of STAT3. We found that STAT3 S754 phosphorylation and 
IRF3 phosphorylation were abrogated with genetic ablation of TBK1 or siRNA-mediated TBK1 
knockdown (Figure 3.3A-B). On the other hand, IKKε knockdown had negligible effects on 
STAT3 S754 or IRF3 phosphorylation (Figure 3.3C), indicating that TBK1 but not IKKε is 
required for cytosolic DNA-induced STAT3 phosphorylation. It has been shown that cytosolic 
DNA also activates IKKα and IKKβ (Figure 3.2B and (13), and that the optimal substrate motif 
of IKKα and IKKβ shares a partial homology to that of TBK1 and IKKε (30,31,34,35). To 
further investigate the role of individual IKKs in promoting STAT3 phosphorylation upon 
cytosolic DNA challenge, we used an IKKα/IKKβ-specific inhibitor compound A (36) and two 
TBK1/IKKε-specific inhibitors AZ-5C and AZ-5E (37). The TBK1/IKKε inhibitors blocked the 
induction of p-IRF3 and pS754-STAT3, while p-p65 was mostly unaffected (Figure 3.3D). Y705 
phosphorylation of STAT3 was also dependent on TBK1 and/or IKKε (Figure 3.3D). In contrast, 
the IKKα/IKKβ inhibitor potently blocked the induction of p-p65 but had minimal effect on p-
IRF3, pS754-STAT3, or pY705-STAT3 in THP-1 cells (Figure 3.3D). This indicates that 
phosphorylation of STAT3 S754 is mediated by TBK1 and is independent of IKKα and IKKβ, 
while activation of NF-κB p65 is mediated by IKKα and/or IKKβ. Taken together, our data 
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demonstrate that TBK1, rather than IKKα, IKKβ, or IKKε, is the principle kinase that mediates 
S754 phosphorylation of STAT3 upon cytosolic DNA challenge. 
 
3.3.4  The cGAS-STING-TBK1 pathway induces STAT3 S754 phosphorylation in response to 
cytosolic DNA 
Because the ER membrane protein STING is indispensible for cytosolic DNA-induced 
TBK1 activation (10,38), we tested if STING is also required for STAT3 S754 phosphorylation 
in response to cytosolic DNA. Indeed, knockdown of STING significantly reduced cytosolic 
DNA-induced pS754-STAT3 (Figure 3.4A). Moreover, pS754-STAT3 can be induced by 
ectopic expression of STING in HEK293T cells in a dose-dependent manner, suggesting that 
S754 phosphorylation occurs downstream of STING activation (Figure 3.4B). We also tested if 
the cytosolic dsDNA sensor cGAS is required in this setting. Knockdown of cGAS led to 
reduced activation of TBK1 and phosphorylation of IRF3, and a moderate reduction in the levels 
of pS754-STAT3 (Figure 3.4C). The moderate reduction of pS754-STAT3 may be due to 
incomplete knockdown of cGAS or the redundancy of other cytosolic DNA sensors. Activation 
of cGAS by cytosolic DNA leads to production of cGAMP, which subsequently promotes 
STING activation and activation of the TBK1-IRF3 signaling axis. We found that transfection of 
cGAMP is sufficient to induce S754 phosphorylation of STAT3 (Figure 3.4D), further 
supporting the model in which S754 phosphorylation of STAT3 occurs downstream of STING. 
These data demonstrate that cytosolic DNA engages cGAS and STING to activate TBK1 and 
induce STAT3 S754 phosphorylation. 
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3.3.5  Secreted cytokines induce activation of STAT3 in response to cytosolic DNA 
We next set out to determine the mechanism of STAT3 activation (as marked by Y705 
phosphorylation) in response to cytosolic DNA. In THP-1 cells, activation of STAT3 was 
suppressed by TBK1/IKKε inhibitors (Figure 3.3D), suggesting that TBK1 kinase activity is 
required for STAT3 activation. Since TBK1 is not a tyrosine kinase, activation of STAT3 is 
likely mediated by tyrosine kinases that are directly or indirectly activated by TBK1. It is well 
established that Janus kinases (JAKs) activate STAT3 by phosphorylating Y705. We thus asked 
if JAKs are involved in STAT3 activation in response to cytosolic DNA. Treating the cells with 
a pan-Janus kinases (JAKs) inhibitor pyridine 6 (39) effectively blocked STAT3 phosphorylation 
at Y705, but TBK1 activation and phosphorylation of STAT3 at S754 was unaffected (Figure 
3.5A). These data and the TBK1 inhibitor data (Figure 3.3D) suggest that cytosolic DNA-
induced STAT3 activation is primarily mediated by JAKs, of which the activation is dependent 
on TBK1. Because JAKs usually function downstream of cytokine receptors, we hypothesized 
that cytosolic DNA induces production of cytokines, leading to activation of the JAKs and 
STAT3 through an autocrine mechanism. An alternative hypothesis would be that TBK1 
activates JAKs directly or through a cascade of kinase activation in a cell-autonomous manner. 
To test these hypotheses, we asked if conditioned media from dsDNA-transfected cells are able 
to activate STAT3 in naive recipient cells. We found that conditioned media from dsDNA 
transfected THP-1 strongly induced pY705-STAT3 but not pS754-STAT3 in the recipient cells 
(Figure 3.5B, lanes 10-14). When cells were treated with cycloheximide immediately before 
dsDNA transfection to block protein synthesis, the ability of conditioned media to induce 
pY705-STAT3 in the recipient cells was abrogated (Figure 3.5B, lanes 15-18). Although the 
possibility of cell-autonomous TBK1-mediated JAKs activation cannot be completely ruled out 
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because a weak STAT3 activation was still observed in cycloheximide-treated cells (Figure 3.5B, 
lanes 6-9), these results argue that STAT3 activation is primarily mediated by de novo 
synthesized secreted factors. We noticed that expression of several STAT3 activating cytokines, 
including IL-6 and IFNβ, was induced by cytosolic DNA, and the induction of IFNβ was blunted 
by TBK1 inhibitor (Supplemental Figure 3.1). Therefore, we tested the involvement of IL-6 and 
IFNβ in STAT3 activation. Indeed, an IFNβ neutralizing antibody reduced the ability of 
conditioned media to activate STAT3 in the recipient cells, and the IL-6 neutralizing antibody 
also had a modest effect (Figure 3.5C). Taken together, our data show that cytosolic DNA-
induced S754 phosphorylation of STAT3 is strictly cell-autonomous, whereas Y705 
phosphorylation, and thus activation of STAT3, is primarily mediated by secreted factors such as 
IFNβ through an autocrine mechanism. 
 
3.3.6  S754 phosphorylation of STAT3 restricts cytosolic DNA-induced STAT3 target gene 
expression 
Next, we sought to determine the effect of cytosolic DNA-induced S754 phosphorylation 
on STAT3 activation and target gene expression. THP-1 cells reconstituted with wild-type or 
mutant STAT3 following CRISPR-mediated knockout (Supplemental Figure 3.2) were 
transfected with dsDNA to induce STAT3 activation and S754 phosphorylation. Activation of 
wild-type and S754D STAT3 by cytosolic DNA was significantly lower than that of the S754A 
mutant, suggesting that S754 phosphorylation inhibits STAT3 activation (Figure 3.6A). STAT1 
and p65 were also activated by cytosolic DNA, but their activation was not affected by the status 
of STAT3, and p65 showed constitutive association with STAT3 (Figure 3.6A). We also 
examined the gene expression induced by cytosolic DNA. STAT3 target gene SOCS3 was 
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upregulated in the presence of STAT3 (Figure 3.6B), and its expression was further elevated in 
the S754A cells, consistent with increased activation of the S754A mutant (Figure 3.6A). The 
NF-κB target gene IL6 was also upregulated in the presence of STAT3, but S754 
phosphorylation did not have any measurable effect on its expression (Figure 3.6C). This 
suggests that there may be cooperative binding and transcriptional activation between STAT3 
and NF-κB in regulating IL-6 transcription, but S754 phosphorylation of STAT3 does not affect 
the gene expression mediated by this complex. In agreement with this hypothesis, the interaction 
between p65 and STAT3 was not affected by cytosolic DNA or the status of S754 
phosphorylation (Figure 3.6A). We also asked if S754 phosphorylation of STAT3 modulates the 
inhibitory effect of STAT3 on ISGF3 target genes (25), and found that CXCL10 was 
downregulated by wild-type and mutant STAT3 to similar levels (Figure 3.6D), suggesting that 
S754 phosphorylation is not involved in the inhibition of ISGF3 target genes by STAT3. Finally, 
chromatin-immunoprecipitation demonstrates that upon cytosolic DNA challenge, STAT3 was 
recruited to the predicted binding sites in SOCS3 promoter (Figure 3.6E), and that the increased 
abundance of S754A STAT3 at the SOCS3 promoter correlated with gene expression levels 
(Figure 3.6B). These data demonstrate that cytosolic DNA-induced S754 phosphorylation of 
STAT3 dampens the expression of STAT3 target gene without affecting the expression of NF-
κB or ISGF3 genes. 
 
3.3.7  S754 phosphorylation suppresses the transcriptional activity of STAT3 
Because S754 is located in the transactivation domain of STAT3, we hypothesized that 
phosphorylation at S754 modulates the transcriptional activity of STAT3 in response to IL-6 and 
IFNβ. We asked if S754 phosphorylation of STAT3 affects the expression of a STAT reporter 
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containing tandem GAS sites in response to IFNβ and IL-6 by using a phosphomimetic mutant 
(S754D), since S754 phosphorylation is not induced by IFNβ or IL-6 alone. To avoid 
interference from endogenous STAT3, the reporter assay was carried out using CRISPR-
mediated STAT3 knockout HEK293T cells (Supplemental Figure 3.2) or STAT3-null MEFs 
stably expressing wild-type or mutant STAT3. We found that IFNβ induced a much higher 
expression of the STAT reporter in the presence of wild-type STAT3, but the transcriptional 
inactive Y705F mutant inhibited reporter expression (Figure 3.7A), indicating that STAT3 
contributes to GAS-driven gene expression in response to IFNβ. The reporter expression was 
reduced with the S754D mutant, suggesting an inhibitory role for S754 phosphorylation in the 
transcriptional activity of STAT3 (Figure 3.7A). In contrast, STAT3 did not affect GAS-driven 
gene expression in response to IFNγ (Figure 3.7A), which predominantly activates STAT1 but 
not STAT3 (15). The S754D mutant also showed decreased activation upon IFNβ stimulation 
(Figure 3.7B), consistent with the results from reporter assays. We then asked if TBK1-induced 
S754 phosphorylation affects STAT3 activation in response to IFNβ. Because overexpression of 
TBK1 leads to significant production of cytokines, resulting in elevated basal STAT3 activation 
(40) (Figure 3.1C), here we expressed a moderate amount of TBK1 before treating the cells with 
IFNβ. We found that TBK1 expression suppressed IFNβ-induced STAT3 activation, but the 
S754A mutant was more refractory to this TBK1-mediated inhibition (Figure 3.7C, lanes 5 and 
7). These data show that S754 phosphorylation inhibits IFNβ-induced activation of STAT3. We 
also probed the possibility that S754 phosphorylation of STAT3 may affect STAT3-mediated 
inhibition on ISGF3 target genes. Consistent with CXCL10 expression in THP-1 cells (Figure 
3.6D), wild-type and mutant STAT3 inhibited IFNβ-induced ISRE reporter expression to 
comparable levels (Supplemental Figure 3.3), indicating that S754 phosphorylation of STAT3 
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does not affect ISGF3 activity. Similar to the IFNβ reporter assays, S754D mutant was also less 
active in response to IL-6 as measured by STAT reporter assays and by the levels of Y705 
phosphorylation, which inversely correlated with the levels of S754 phosphorylation or 
phosphomimetic mutation (Figure 3.7D-E). Collectively, these data demonstrate that S754 
phosphorylation suppresses the transcriptional activity of STAT3 induced by IL-6 and IFNβ. 
 
3.4  Discussion 
In this study, we identified STAT3 as a novel substrate of TBK1 downstream of the 
cytosolic DNA pathway. In the presence of cytosolic DNA, TBK1 phosphorylates STAT3 at 
S754 to limit STAT3 activity induced by cytokines such as IL-6 and IFNβ. Previously, it has 
been shown that IKKε regulates STAT1 dimerization and that TBK1 regulates STAT6 activity 
by direct phosphorylation (14,26). Our finding places a third STAT member under the control of 
IKKε/TBK1. Interestingly, the IKKε/TBK1-mediated phosphorylation sites in STAT1, STAT3, 
and STAT6 differ in their location within the proteins (Figure 3.1A). In the case of STAT1, 
phosphorylation of S708, which resides in between the SH2 domain and the TAD, disrupts SH2 
domain-mediated STAT1 homodimerization by steric hindrance (26). How TBK1-mediated 
S407 phosphorylation regulates the activity of STAT6 is less clear. S407 resides within a highly 
conserved region of STAT DNA binding domain, and structural analysis demonstrated that 
mutations in this region abolish the DNA binding ability of STATs (41). Thus, it is plausible that 
S407 phosphorylation affects the DNA binding affinity of STAT6. It is also worth noting that 
TBK1 induces a reduced but still significant phosphorylation on STAT6 S407A mutant (14), 
suggesting the existence of additional TBK1 phosphorylation sites in STAT6. In fact, we 
identified another IKKε/TBK1 substrate motif in STAT6 TAD, in which S733 is the residue that 
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corresponds to S754 of STAT3. Our preliminary data suggest that TBK1 overexpression also 
leads to STAT6 phosphorylation at S733 (H-.C. Hsia, unpublished data). For future 
investigations, it would be of interest to determine if this phosphorylation serves as an additional 
mechanism by which TBK1 regulates STAT6 activity in a manner similar to what we discovered 
with STAT3. 
The two IKK-related kinases TBK1 and IKKε are structurally similar and prefer almost 
identical substrate sequences in vitro (30,31). However, they appear to have distinct yet partially 
overlapping roles in vivo (42). Studies using TBK1 or IKKε knockout cells showed that TBK1 is 
the principle kinase that phosphorylates IRF3 to initiate interferon production in response to 
innate immune stimuli and pathogens, while IKKε has a minor or negligible role on activating 
IRF3 and interferon production (11,43,44). Similarly, in our model, although overexpression of 
TBK1 and IKKε both induced S754 phosphorylation of STAT3 (Figure 3.1B, 3.1C), endogenous 
IKKε did not have a measurable impact on STAT3 phosphorylation in response to VACV70mer 
(dsDNA with 33% GC content) transfection (Figure 3.3C). However, it is worth noting that 
while VACV70mer only induced interaction between STAT3 and TBK1, poly(dA:dT) 
transfection induced interaction of STAT3 with TBK1 and IKKε (Figure 3.2B), suggesting that 
IKKε may contribute to the signaling cascades and STAT3 phosphorylation downstream of AT-
rich cytosolic DNA. AT-rich cytosolic DNA not only activates the STING/TBK1 pathway but 
also engages the cytosolic dsRNA sensor RIG-I by a polymerase III-dependent mechanism (45). 
Thus, the differential interactions between STAT3 and IKKε/TBK1 in response to VACV70mer 
and poly(dA:dT) may be due to the activation of cytosolic dsRNA pathway specifically 
downstream of poly(dA:dT). It is also conceivable that IKKε will play a more dominant role in 
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scenarios where its expression is highly induced (46). Whether IKKε contributes to STAT3 S754 
phosphorylation and regulation under these conditions remains to be tested. 
The NF-κB pathway is also activated by cytosolic DNA, but the roles of different IKKs 
in this context remain controversial (11-13). Ishii et al. suggested that TBK1 is dispensable for 
cytosolic DNA-induced NF-κB activation (11), while Abe and colleagues demonstrated a 
significant dependence of NF-κB activation on TBK1 (12,13). In MEFs and THP-1 cells, we 
observed that IKKα/IKKβ and TBK1 are each responsible for cytosolic DNA-induced p65 NF-
κB activation or IRF3 activation (Figure 3.3A, 3.3D), indicating that the signaling events 
dictating NF-κB and IRF3 activation diverge at or above the level of these kinases. Intriguingly, 
p65 activation in L929 is mostly dependent on TBK1 (Figure 3.3B), consistent with the 
observation made by Abe et al. (13). It is unclear why such differences exist. One possible 
explanation may be the availability of different signaling molecules and the formation of 
different complexes. For instance, depending on the cell type, TBK1 may localize to the 
mitochondria or the ER in response to cytosolic DNA (47). Therefore, it is likely that signaling 
pathways downstream of cytosolic DNA and STING may be influenced by the availability of 
cell type-specific machinery and platforms as well as the subcellular localization of TBK1. 
While it is unclear why S754 phosphorylation dampens the activity of STAT3, studies on 
a natural occurring STAT3 isoform STAT3β provide a plausible hypothesis. Alternative splicing 
of the STAT3 transcript results in the truncated STAT3β isoform that is 48 amino acids shorter 
than the full-length STAT3 (48). STAT3β shows strong Y705 phosphorylation and DNA binding 
activity even in the absence of stimulation, but it lacks intrinsic transcriptional activity due to the 
lack of TAD (48,49). Interestingly, STAT3β dimers are more stable than dimers formed by full-
length STAT3, and deletion of 19 residues at the C-terminus (amino acids 752-770) of full-
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length STAT3 is sufficient to significantly enhance Y705 phosphorylation, DNA binding 
activity, and dimer stability (50). Because the C-terminus of STAT3 is rich in acidic amino acids 
that are negatively charged, it was therefore proposed that the cluster of negative charges in the 
TAD interferes STAT3 dimerization and makes phosphorylated Y705 more accessible to 
phosphatases (50). Given this mechanism, phosphorylation or phosphomimetic mutation of S754 
will introduce more negative charges to the region and may destabilize STAT3 dimers, thereby 
reducing its transcriptional activity. Alternatively, it is also possible that S754 phosphorylation 
affects the interaction between STAT3 and its co-activators to modulate STAT3 activity. Future 
studies will be focusing on testing these hypotheses. 
There is mounting evidence of the critical role of cytosolic DNA in tumorigenesis and 
anti-tumor immune responses. Functional loss of the cGAS/STING cytosolic DNA pathway has 
been observed in some commonly used cell-lines and high-passage immortalized MEFs (5) as 
well as colorectal cancer and melanoma, in which loss of the cytosolic DNA pathway correlates 
with tumor progression (27,28). In a mouse model of colitis-associated colorectal cancer, STING 
deficient mice showed elevated NF-κB and STAT3 activity and developed advanced disease, 
suggesting a role of STING in controlling inflammatory responses and tumorigenesis (29). 
According to our model, loss of the cytosolic DNA sensing pathway will predict loss of the 
TBK1-mediated restraint on STAT3 activity, allowing the tumor cells to have elevated STAT3 
activation in response to cytokines such as IL-6. Given the well-established role of STAT3 in 
promoting tumorigenesis, our finding suggests a possible mechanism in which tumor cells 
without the cytosolic DNA pathway may have a survival advantage due to unchecked STAT3 
activation. On the other hand, activation of dendritic cells (DC) in the tumor microenvironment 
by engaging the cGAS/STING pathway leads to significant T cell recruitment and anti-tumor 
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immunity (51,52). Since STAT3 negatively regulates DC activity and the anti-tumor response of 
hematopoietic cells (20,53), cytosolic DNA-mediated restraint on STAT3 activity may serve as 
an additional mechanism to strengthen the anti-tumor immunity of hematopoetic cells in the 
tumor microenvironment.  
In summary, we identified a novel signaling axis in which TBK1 modulates STAT3 
activity in response to cytosolic DNA. Our findings reveal a new mechanism by which the 
activity of STAT3 can be fine-tuned by a single phosphorylation, and shed lights on the possible 
crosstalks between innate immune responses and STAT3-driven oncogenic pathways.  
 
3.5  Materials and Methods  
Plasmids and viruses. Mouse STAT3 was cloned into pBabe-puro (Addgene #1764)(54) 
using BamHI and EcoRI. N-terminal HA-tagged STAT3 was cloned into 3XHA-pEBB vector 
using BamHI and NotI. N-terminal FLAG-tagged STAT3 was cloned into pENTR-3C plasmid 
using BamHI and EcoRI, followed by Gateway recombination into pLenti6/UbC/V5 destination 
vector (Thermo Fisher). The C terminus of STAT3 (amino acids 700-770) was cloned into 
pGEX-4T-1 in frame with N-terminal GST using BamHI and EcoRI. STAT3 mutant plasmids 
were generated by site-directed mutagenesis and confirmed by sequencing. STAT3 CRISPR 
plasmid was constructed using lentiCRISPRv2 (Addgene #52961) (55) with an sgRNA targeting 
5’ UTR of human STAT3 (Supplemental Figure 3.2). The primer sequences for sgRNA cloning 
are as follows: 5’-CAC CGT GCC GGA GAA ACA GGT GAA G-3’, 5’-AAA CCT TCA CCT 
GTT TCT CCG GCA C-3’. 
Protein purification and in vitro assays. Rosetta cells (Novagen) harboring pGEX-4T-
1-STAT3 plasmid were grown to log-phase and treated with 0.5 mM of IPTG at 30°C for 16 
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hours. The cells were lysed (50 mM Tris pH 7.6, 150 mM NaCl, 1 mM EDTA, 5 mM DTT, 25 
µg/ml lysozyme, protease inhibitor cocktail (Promega)) at room temperature, followed by 
addition of 1.25 µg/ml of sodium deoxycholate, 1.25 µM of MgCl2, and 62.5 µg/ml of DNase I. 
Cleared lysates (13000 rpm, 15 min, 4°C) were incubated with glutathione agarose beads 
(Amersham) at 4°C for 2 hours. The beads were washed twice with modified RIPA (150 mM 
NaCl, 1% NP-40, 0.25% sodium deoxycholate, 50 mM Tris pH 7.6, 1 mM β-glycerol 
phosphate), twice with high salt (500 mM NaCl) modified RIPA, and twice with kinase buffer (1 
mM β-glycerol phosphate, 20 mM Tris pH 7.4, 12 mM MgCl2). Purified protein was eluted by 
incubating the beads with 30 mM glutathione in kinase buffer with 0.1% Tween 20 for 20 
minutes at room temperature with shaking. Wild-type and K38A GST-TBK1 were purified from 
HEK293T transfected with pEBG-GST-TBK1 plasmids as previously described (31). For in 
vitro kinase assays, 1 to 2 µl of purified GST-STAT3 was incubated with 2 to 4 µl of wild-type 
GST-TBK1 or K38A GST-TBK1 in kinase buffer with 1 mM ATP and 10 µCi of 32P-γ-ATP at 
room temperature for 2 hours. The reaction was resolved by SDS-PAGE followed by 
immunoblotting or autoradiography. 
Cells. THP-1 cells were maintained in RPMI1640 with 10% FBS, while HEK293T, 
L929, and MEFs were maintained in DMEM with 10% FBS and kept at 37°C with 5% CO2. 
STAT3-null MEFs were a gift from Dr. Hua Yu (City of Hope), and TBK1 null MEFs were a 
gift from Amgen. Retroviruses were produced by co-transfection of pBabe-puro-STAT3 and 
pCL10A1 plasmids into HEK293T cells, and lentiviruses were produced by co-transfection of 
pLenti6-STAT3 with psPAX2 and pMD2.G into HEK293T cells. The supernatants containing 
viruses were 0.45 um-filtered before being used for transduction. To reconstitute STAT3 
expression in STAT3-null MEFs, MEFs were transduced with pBabe-puro-STAT3 retroviruses 
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and selected for puromycin resistance. To generate STAT3 CRISPR knockout cells, THP-1 or 
HEK293T cells were transduced with STAT3 CRISPR virus and selected for puromycin 
resistance, and single clones were analyzed for STAT3 knockout efficiency (Supplemental 
Figure 3.2). To reconstitute STAT3 in THP-1, deltaSTAT3-THP-1 cells were transduced with 
pLenti6-STAT3 viruses and selected for blasticidin resistance. To activate TBK1, cells were 
transfected with poly (I:C), poly (dA:dT), VACV70mer, or 2’-3’ cGAMP using lipofectamine 
2000 (Thermo Fisher) at 1:1 ratio (µg/µl), and the final concentration of nucleic acids was 2 
µg/ml unless otherwise noted. THP-1 cells were treated with 25 ng/ml of PMA (Sigma #P1585) 
overnight to induce adherence before cytosolic DNA transfection. Poly(I:C) (#tlrl-pic) 
poly(dA:dT) (#tlrl-patn), cGAMP (#tlrl-cga23), and LPS (#tlrl-eblps) were from Invivogen. 
VACV70mer was prepared by annealing complimentary 70-nt primers as previously described 
(33). For conditioned media experiments, supernatants from nucleic acid transfected cells were 
collected and 0.2 µm-filtered, mixed with 20 µg/ml of normal mouse IgG (Millipore, 12-371), 20 
µg/ml of human IL-6 neutralizing antibody (R&D Systems #MAB206), or 40 µg/ml of human 
IFNβ neutralizing antibody (BioLegend #514004), and incubated at room temperature for 20 
minutes before being added to recipient cells. 
Transfection of siRNA. Transfection of siRNA was carried out using lipofectamine 
2000 according to manufacturer’s protocol. Mouse Tbk1 (#M-063162-01-0005), mouse Ikbke 
(IKKε) (#M-040798-01-0005), mouse Tmem173 (STING) (#M-055528-01-0005), and control 
siRNAs (#D-001210-03-05) were from Dharmacon. Mouse Mb21d1 (cGAS) siRNA was from 
Sigma (#SASI_Mm01_00129826) 
Reporter assays. The STAT reporter 4xM67 pTATA TK-firefly luciferase plasmid 
(Addgene #8688) (56) and pRL-TK-renilla luciferase plasmid (Promega) were co-transfected at 
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15:1 to 20:1 ratios into deltaSTAT3 293T cells together with 4xHA-STAT3 plasmids. Twenty-
four hours after transfection, cells were treated with 25 pg/ml of mouse IFNβ (R&D Systems, 
8499-IF-010) or 200 pg/ml of mouse IFNγ (R&D Systems, 285-IF-100). Cells were lysed with 
passive lysis buffer (Promega) for dual-luciferase assay (Promega) at 16-24 hours after 
treatment. The relative luciferase unit (RLU) was calculated by normalizing the reading of firefly 
luciferase to that of renilla luciferase, and RLU of the control cells was set to one. For IL-6 
reporter assays, STAT3 reconstituted MEFs were transfected with reporters in the same manner 
and treated with 100 ng/ml of mouse IL-6 (BioLegend, 575704) for 24 hours. 
Immunoblotting and immunoprecipitation. For immunoblotting, cells were lysed in 
RIPA buffer with protease inhibitor cocktail (Promega), phosphatase inhibitor cocktail (Sigma), 
and 1 mM Na3VO4. Cleared lysates were resolved by SDS-PAGE (NuPAGE bis-tris gels, 
Thermo Fisher), transferred to PVDF membranes (Millipore #IPVH00010), and blocked in 5% 
non-fat milk in TBST. The membranes were incubated in primary antibodies (1:1000-1:5000) in 
TBST at 4°C overnight, washed with TBST, and incubated in appropriate HRP-conjugated 
secondary antibodies (Promega) (1:10000). Pierce ECL (Thermo Fisher) was added to the blots, 
which were then exposed to films and developed, or imaged using ChemiDoc (BioRad). For 
immunoprecipitation, cells were lysed in 0.5% NP-40 buffer (0.5% NP-40, 150 mM NaCl, 20 
mM Tris pH 7.6, 1 mM EGTA, 1 mM EDTA, 1 mM β-glycerol phosphate, and 0.5% glycerol) 
with protease and phosphatase inhibitors and Na3VO4. Cleared lysates were incubated with M2 
Flag (Sigma) or STAT3 antibodies at 4°C overnight, followed by incubation with dynabeads 
protein G (Thermo Fisher) for 1 hour at 4°C and washing with 0.5% NP-40 buffer, and resolved 
by SDS-PAGE and immunoblotting. The following antibodies were from Cell Signaling 
Technology: GST (#2624, #2625), p-IKKα/IKKβ (S176/S180) (#2697), IKKβ (#2684), IKKε 
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(#3416), p-IRF3 (S396) (#4947), IRF3 (#4302), p-TBK1 (S172) (#5483), TBK1 (#3013), p-
STAT3 (Y705) (#9145, #9132), p-STAT3 (S727) (#9134), p-p65 (S536) (#3033), p65 (#8242), 
STING (#13647), p-STAT3 (S754) (BL14578: 5163), and IKK phospho-substrate motif 
(G9108). The IKK p-substrate motif antibody was generated against the phosphorylated IKK 
consensus sequence x-(Y/F)-x-pS-L-x, where pS is the phospho-serine targeted by IKKs 
(30,31,34,35). GAPDH (sc-25778) and β-tubulin (sc-9104) antibodies were from Santa Cruz. 
Densitometry analyses were carried out using the gel analysis function of ImageJ. 
 Chromatin immunoprecipitation (ChIP). ChIP was performed as previously described 
(57). Briefly, cells were fixed by formaldehyde, lysed, and sonicated to yield DNA fragments of 
200-500 bp. Lysates were diluted to 0.1% of SDS and precleared by incubating with BSA and 
salmon sperm DNA-blocked Dynabead magnetic protein G beads (Thermo Fisher). Lysates 
corresponding to 5x106 cells were used for each ChIP with 5 µg of rabbit IgG (Cell Signaling 
Technology #2729) or rabbit anti-STAT3 antibody (Cell Signaling Technology #12640), 
followed by capture with Dynabead magnetic protein G beads. DNA-protein-antibody 
complexes were eluted, and DNA was un-crosslinked and purified by phenol-chloroform. The 
quantity of input DNA was determined by Nanodrop. The quantity of DNA corresponding to the 
STAT3 binding site in SOCS3 promoter in immunoprecipitated chromatin was determined by 
qRT-PCR with three technical repeats using SYBR green (Thermo Fisher) and the following 
primers: 5’-TAA GAA GGC TGA TTT CTG GCA GAG G-3’, 5’-CCA GGT CGG CCT CCT 
AGA ACT-3’. Data are shown as mean with standard deviation, and are representative of two 
independent experiments. 
Quantitative real-time PCR. Total RNA from cells were purified using QIAGEN 
RNeasy Plus kit according to manufacturer’s protocol. One to 2 µg of RNA was used to 
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synthesize cDNA using M-MLV reverse transcriptase (Thermo Fisher). Quantitative real-time 
PCR (qRT-PCR) was carried out using synthesized cDNA, and tandard TaqMan probes, primers, 
and reagents (Thermo Fisher). The expression level of target genes was calculated by ddCt 
method relative to the level of GUSB. Data shown were the relative quantity (RQ), with RQ of 
the control cells set to one. 
Statistical analysis. For reporter assays and qRT-PCR, data were shown as mean with 
standard deviation or mean with 95% confidence intervals, respectively. Each data point was 
from three technical replicates. Analyses were done by Prism (Graphpad) using t-test with FDR 
controlled at 1%. 
Inhibitors and reagents. The IKKα/IKKβ-specific inhibitor Compound A was a 
generous gift from Dr. Karl Ziegelbauer (Bayer). The TBK1/IKKε-specific inhibitors AZ-5C and 
AZ-5E were synthesized by Dr. Stephen Frye’s group at UNC-Chapel Hill. The pan-JAK 
inhibitor pyridone 6 was from Millipore (#420099), and cycloheximide was from Sigma 
(#C7698). 
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Figure 3.1  IKKε and TBK1 induce STAT3 phosphorylation at S754 
(A) A schematic figure showing the domain structure of STAT3 and the location of S754. 
Sequences of STAT3 from several vertebrates were aligned to compare the homology, with 
residues critical for TBK/IKKε substrate recognition marked in blue, and S754 marked in red. 
Also shown are the domain structure of STAT1 and STAT6, with previously identified 
IKKε/TBK1 target serine residues marked in red and the sequence alignments shown on the 
right. NTD: N-Terminal domain; SH2: Src homology 2. (B) Flag-tagged STAT3 (3 µg) was co-
transfected with GST-IKKε (3 µg) into HEK293T cells. STAT3 was immunoprecipitated and 
blotted with an IKK substrate motif antibody. (C) Flag-tagged wild-type, Y705F, S727A, or 
S754A STAT3 (3 µg) were co-transfected with wild-type or K38A (kinase dead, KD) GST-
TBK1 (3 µg) into HEK293T cells. STAT3 was immunoprecipitated and blotted with 
phosphorylation-specific antibodies to detect S754, Y705, and S727 phosphorylation. (D) In vitro 
kinase assay using GST-tagged C-terminus of STAT3 and GST-TBK1 purified from HEK293T 
as described in Experimental Procedures. The mixture was resolved by SDS-PAGE and blotted 
with GST and pS754-STAT3 antibodies. Phosphorylation of STAT3 was also detected by 
autoradiography. Data in (B-D) are representative of 4, 3, and 2 independent experiments.  
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Figure 3.2  Cytosolic DNA induces STAT3 activation and phosphorylation at S754 
(A) L929 cells were transfected with poly (I:C), poly (dA:dT), VACV70mer (hereafter referred 
to as dsDNA) using lipofectamine 2000, or treated with 1 µg/ml of LPS, or serum starved for 3 
hours. Lysates were analyzed by western blotting to determine the levels of TBK1, IRF3, and 
STAT3 activation. (B) THP-1 cells were treated as described in (A), or treated with 1 µg/ml of 
flagellin for 3 hours. Lysates were analyzed by western blotting, and STAT3 was 
immunoprecipitated and blotted for co-precipitated IKKε or TBK1. (C) A time-course analysis 
of signaling responses to cytosolic DNA. THP-1 cells were mock-transfected or transfected with 
dsDNA and analyzed by western blotting at indicated times. STAT3 was immunoprecipitated 
and blotted for p-S754 and co-precipitated TBK1. Data in this figure are representative of 2 
independent experiments.  
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Figure 3.3  TBK1 activity is required for cytosolic DNA-induced S754 phosphorylation of 
STAT3 
(A) Wild-type or TBK1 knockout MEFs were transfected with 5 µg/ml of dsDNA and analyzed 
by western blotting at indicated time points. (B) L929 cells were transfected with control siRNA 
or TBK1 siRNA. Forty-eight hours after siRNA transfection, cells were transfected with dsDNA 
and analyzed by western blotting. (C) L929 cells were transfected with control siRNA or IKKε 
siRNA. Sixty-eight hours after siRNA transfection, cells were transfected with dsDNA and 
analyzed by western blotting. (D) THP-1 cells were pretreated with DMSO, 5 µg/ml of 
compound A (an IKKα/IKKβ inhibitor), or 2 µM of AZ-5C or AZ-5E (IKKε/TBK1 inhibitors) 
for 30 minutes, followed by transfection with dsDNA for 3 hours. Cells were lysed and blotted 
for p-TBK1, p-IRF3, p-p65, and p-STAT3 to determine the activation of corresponding 
pathways. Data in (A-C) and (D) are representative of 2 and 3 independent experiments, 
respectively.  
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Figure 3.4  Cytosolic DNA induces pS754-STAT3 via the cGAS/STING axis 
(A) L929 cells were transfected with control or IKKε siRNA. Forty-eight hours post-
transfection, cells were transfected with dsDNA and analyzed by western blotting at indicated 
time points. (B) Increasing amount of STING expression plasmid was transfected into HEK293T 
cells with decreasing amount of pcDNA3 empty vector, such that same amount of total DNA 
was used in every transfection. After 24 hours, cells were lysed and blotted for pS754-STAT3. 
GST-TBK1 transfected cells were used as a positive control. (C) L929 cells were transfected 
with control or cGAS siRNA. After 68 hours, cells were harvested for qRT-PCR to measure 
cGAS expression levels, or transfected with dsDNA for 3 hours and analyzed by western 
blotting. The expression of cGAS was normalized to Gusb. (D) L929 cells were mock-
transfected or transfected with cGAMP and analyzed by western blotting. Data in (A) and (B-D) 
are representative of 3 and 2 independent experiments, respectively.  
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Figure 3.5  Cytosolic DNA-induced STAT3 activation is mediated by de novo synthesized 
secreted factors 
(A) THP-1 cells were pre-treated with DMSO or 100 nM of the pan-JAK inhibitor pyridone 6 for 
30 minutes, followed by transfection of dsDNA. Cells were analyzed by western blotting at 
indicated time points. (B) THP-1 cells were left untreated or treated with 30 µg/ml of 
cycloheximide (CHX) to block protein synthesis. After 1 hour of treatment, cells were 
transfected with dsDNA and lysed for western blotting at indicated time points, and results are 
shown in the left half of the blots. Conditioned media (CM) were collected from the dsDNA-
transfected cells at the same time points, applied to naïve recipient cells for 20 minutes, and 
results are shown in the right half of the blots. (C) THP-1 cells were transfected with dsDNA, 
and conditioned media (CM) were collected at 2, 3, or 4 hours after transfection. Conditioned 
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media were incubated with 20 µg/ml of control IgG, 20 µg/ml of IL-6 neutralizing antibody, or 
40 µg/ml of IFNβ neutralizing antibody for 20 minutes, and applied to naïve recipient cells for 
20 minutes before western blotting. Data in this figure are representative of 3 independent 
experiments.  
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Figure 3.6 . S754 phosphorylation restricts STAT3 activation in response to cytosolic DNA 
(A) deltaSTAT3 THP-1 cells reconstituted with wild-type or mutant STAT3 were transfected 
with dsDNA for 2 or 4 hours. Cells were analyzed by western blotting to assess the activation of 
STAT1, STAT3, and NF-κB p65. (B-D) deltaSTAT3 and reconstituted THP-1 cells were treated 
as described in (A), and RNA was collected for qRT-PCR to determine the expression levels of 
SOCS3, IL6, and CXCL10. *** p<0.001, ** p<0.01, n.s. not significant, n.d. not determined 
(below detection threshold). (E) A diagram of the SOCS3 promoter showing predicted STAT3 
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binding sites (gray boxes), with numbers indicate locations relative to the transcription starting 
site (TSS). Enrichment of STAT3 at the distal binding site was determined by ChIP as described 
in Experimental Procedures. Immunoprecipitated DNA from control or dsDNA transfected (3 
hours) THP-1 cells was quantified by qRT-PCR using primers corresponding to the arrows in the 
diagram. The quantities of immunoprecipitated DNA are shown as percentages of input DNA. 
Data in (A-B) are representative of 4 independent experiments, and data in (C-E) are 
representative of 2 independent experiments.   
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Figure 3.7  S754 phosphorylation inhibits transcriptional activity of STAT3 
(A) Dual luciferase assay was used to determine STAT3 activity as described in Experimental 
Procedures. deltaSTAT3 HEK293T cells in 12-well plates were transfected with 0.5 µg of empty 
vector (EV) or 4xHA-STAT3 plasmids, 0.5 µg of STAT firefly luciferase plasmid, and 25 ng of 
TK-renilla luciferase plasmid, followed by treatment with 25 pg/ml of human IFNβ or 200 pg/ml 
of human IFNγ. Cell lysates were used for western blotting to verify STAT3 expression levels. 
Data are shown as mean with standard deviation. ***p<0.001 (B) deltaSTAT3 HEK293T cells in 
6-cm plates were transfected with 3 µg of 4xHA-STAT3 plasmids. Twenty-four hours after 
transfection, cells were treated with 20 pg/ml of human IFNβ for 30 minutes, and lysed for 
western blotting. Densitometric ratios of pY705-STAT3 to STAT3 were shown to evaluate the 
levels of STAT3 activation. (C) deltaSTAT3 HEK293T cells in 10-cm plates were transfected 
with 3 µg of 4xHA-STAT3 plasmids and 1 µg of wild-type or kinase-dead GST-TBK1 plasmids. 
Twenty-four hours after transfection, cells were treated with 20 pg/ml of human IFNβ and lysed 
for western blotting. Densitometric ratios of pY705-STAT3 to STAT3 were shown to evaluate 
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the levels of STAT3 activation. (D) STAT3-null MEFs reconstituted with wild-type or mutant 
STAT3 in 12-well plates were transfected with 0.5 ug of STAT firefly luciferase reporter and 33 
ng of tk-renilla luciferase plasmid, followed by treatment of 100 ng/ml of mouse IL-6 before 
dual luciferase assays. Data were shown as mean with standard deviation. ***p<0.001 (E) 
STAT3-null MEFs reconstituted with wild-type or mutant STAT3 were treated with 30 ng/ml of 
mouse IL-6 for 30 minutes and analyzed by western blotting to determine the levels of STAT3 
activation. Data in (A), (B-C), (D-E) are representative of 3, 2, and 4 independent experiments, 
respectively.  
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Figure 3.8  Schematic overview of STAT3 activation and regulation downstream of the 
cytosolic DNA pathway 
Works presented in this chapter show that TBK1 directly phosphorylates STAT3 at S754 in 
response to cytosolic DNA in a cGAS and STING-dependent manner. Meanwhile, activation of 
IRF3 and NF-κB leads to production of IL-6 and IFNβ, which in turn activate STAT3 via JAKs. 
TBK1-mediated phosphorylation of S754 dampens STAT3 activity as demonstrated by reduced 
expression of the STAT3 target gene SOCS3.  
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Supplemental Figure 3.1  Cytosolic DNA induces expression of IFNβ and IL-6 
(A) THP-1 cells were transfected with dsDNA, and the expression levels of IFNB1 and IL6 at 2 
and 4 hours post-transfection were determined by qRT-PCR. (B) THP-1 cells were pretreated 
with 1 or 2 µM of TBK1 inhibitor (AZ-5C) for 30 minutes, and transfected with dsDNA 
transfection for 8 hours. Expression levels of IFNB1 and IL6 were determined by qRT-PCR.  
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Supplemental Figure 3.2  CRISPR-mediated knockout of STAT3 in HEK293T and THP-1 
(A) A schematic figure showing the target site of STAT3 sgRNA #6 at the 5’ UTR of human 
STAT3 transcript. Potential off-targets of STAT3 sgRNA #6 were summarized in the table. (B) 
HEK293T cells were transduced with plentiCRISPRv2-STAT3-sgRNA6 virus. Puromycin-
resistant individual clones were selected and analyzed by western blotting to determine the 
efficiency of STAT3 kncokout. Subclone #6 was designated as deltaSTAT3 HEK293T and used 
for the experiments in this paper. (C) THP-1 cells were transduced with three different plenti-
CRISPRv2-STAT3 sgRNA viruses. Cells transduced with sgRNA#6 were further selected for 
puromycin-resistant individual clones. Subclone #2 were designated as deltaSTAT3 THP-1, 
reconstituted with wild-type or mutant STAT3, and used for experiments shown in Figure 3.6.  
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Targeting Exon1/intron junction, 5’UTR of STAT3 transcript 
Exon 1 Exon 2 
ATG . 
sgRNA #6 
Off-targets 
No off-targets with 0, 1, or 2 mismatches 
Gene # of mismatches Sequence 
Keratin 20 (intron) 3 CCCCTTCtCCTGTTTCTCCcGCt 
TMEM17 (intron); 
LOC105374764 (intron) 3 TGCCtGtGAAACAGGTGAAtGGG 
Mitogen-activated protein 
kinase 11 (intron) 3 CCCCTTCtCCTGTTTCcCCtGCA 
A
B C
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Supplemental Figure 3.3  STAT3 inhibits IFNβ-induced ISRE reporter expression 
deltaSTAT3 293T cells were transfected with 167 ng of 4xHA-STAT3 plasmids, 167 ng of ISRE 
firefly luciferase plasmid, and 9 ng of tk-renilla luciferase plasmid. Twenty-four hours after 
transfection, cells were treated with 25 pg/ml of human IFNβ for another 24 hours before dual 
luciferase assay.  
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CHAPTER 4: FUTURE DIRECTIONS AND CONCLUSIONS
 In this Chapter, I examine how the discoveries described in this dissertation add to our 
current understanding of the roles and regulation of STAT3 in diseases, and present unpublished 
data to discuss future directions revealed by my research. 
 
4.1  Roles and Regulation of STAT3 Activity in Diseases 
4.1.1  Regulation of STAT3 activity: A balancing act 
The ubiquitous expression of STAT3 and its activation by a number of cytokines and 
activators give STAT3 a central role in controlling the survival, proliferation, and function of 
cells. Consequently, dysregulation of STAT3 activity is associated with numerous diseases and 
disorders. In humans, STAT3 loss-of-function mutations lead to the immunodeficiency disorder 
AD-HIES as discussed in Chapter 1. AD-HIES patients have higher incidences of herpesvirus 
reactivation and viremia, and these symptoms have been partially attributed to T cell-intrinsic 
defects (1). My work presented in Chapter 2 showed that myeloid-specific STAT3 knockout 
mice are also more susceptible to HSV-1 (2,3). Specifically, these knockout mice exhibited an 
attenuated type I IFN response and defects in DC and NK cell activation, indicating that STAT3 
is required by the myeloid cells to elicit effective innate immune responses against herpesvirus 
infections. On the other hand, STAT3 gain-of-function mutations cause lymphoproliferative 
disorders and cancers in human. It is also well established that constitutive STAT3 activation 
contributes to increased metastasis, resistance to therapy, and poor prognosis in a variety of 
cancers (discussed in Chapter 1). Thus, precise temporal and spatial regulation of STAT3 
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activity is crucial to maintaining homeostasis and establishing effective defense against 
pathogens. 
Regulation of transcription factor activity can be achieved through several means, but 
regulation of activity by post-translational modification (PTM) offers the advantage of 
instantaneous response and flexibility in timespans. Several PTMs have been reported to fine-
tune STAT3 activity, including K49 dimethylation, K685 acetylation, and S727 phosphorylation, 
all of which has been suggested to increase STAT3 activity (4-8). The S754 phosphorylation 
identified in Chapter 3 adds a novel inhibitory mechanism to the growing means of STAT3 
activity regulation by PTM. The inhibitory effect of S754 phosphorylation on STAT3 activity 
suggests that it may modify cellular responses by regulating STAT3 target gene expression, 
necessitating the need to understand the gene expression profile affected by S754 
phosphorylation of STAT3. It is unclear whether all STAT3 target genes or only a subset of 
targets are repressed by S754 phosphorylation. Although the DNA binding specificity of STAT3 
is dictated by its DBD (9), it is still conceivable that S754 phosphorylation may modify the 
promoter preference of STAT3 by altering the interaction between STAT3 and other 
transcription factors or co-factors, and consequently change the selectivity of STAT3 toward 
specific target genes depending on the available transcription factors and co-factors at a given 
moment. Moreover, a transcriptional repression role of STAT3 has also been reported for some 
genes (10,11). Whether S754 phosphorylation has any impact on the transcriptional repression 
mediated by STAT3 remains to be determined. For future investigations, comparing the cytosolic 
DNA-induced promoter occupancy of STAT3 and gene expression of WT and S754A STAT3 
reconstituted cells by ChIP-seq and RNA-seq may provide some clues to these questions. 
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4.1.2  Regulation of STAT3 activity in viral infection 
The finding that cytosolic DNA restrains STAT3 activation by S754 phosphorylation 
raises several important questions: When and where does this occur in vivo, and what are the 
consequences? One possible scenario that may lead to STAT3 S754 phosphorylation is during 
DNA virus infection, which is known to activate the cytosolic DNA pathway. As a negative 
regulator of STAT1 and IFN response, STAT3 deficiency confers improved resistance to viral 
infections in cell culture (12), but permanent functional loss of STAT3 in vivo leads to impaired 
immune responses to bacterial and viral infections (Chapters 1 and 2). Therefore, a transient and 
controlled inhibition of STAT3 activity by S754 phosphorylation may be beneficial to the host 
defense without causing long-term detrimental effects. Indeed, my preliminary data showed that 
WT HSV-1 infection induced a modest STAT3 S754 phosphorylation in STAT3 reconstituted 
MEFs, although WT and S754A MEFs did not have a measurable difference in their intrinsic 
resistance to HSV-1 replication (data not shown). One possible explanation is that modest 
STAT3 inhibition is not sufficient to overcome the effective repression of TBK1 and IFN 
responses by HSV-1 (13,14), and using an attenuated strain of HSV-1 with reduced ability to 
inhibit TBK1 may help reveal the subtle differences between WT and S754A STAT3 cells. 
Additionally, it may be worth examining the gene expression profile in HSV-1 infected WT and 
S754A reconstituted cells, since differential gene expression, if involving cytokines and secreted 
factors, is likely to affect the course of viral pathogenesis and clearance in vivo.  
 
4.1.3  Regulation of STAT3 activity in tumors and the tumor microenvironment 
The tumor microenvironment is another possible scenario in which STAT3 can become 
phosphorylated at S754. It was known that cytosolic DNA can activate DC and act as a potent 
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adjuvant for vaccination before the molecular mechanism of the cytosolic DNA pathway was 
fully understood (2,3). Recent studies showed that DC in the tumor microenvironment are 
activated by tumor-derived DNA in a STING-dependent manner, resulting in IFNβ secretion and 
T cell recruitment to the tumor (4-8,15). Although these infiltrating T cells are often functionally 
repressed, this “T cell-inflamed” tumor microenvironment predicts better responses to check-
point inhibitor immunotherapies (9,16). Since STAT3 is a negative regulator of DC activity 
(10,11,17), it is tempting to speculate that tumor-derived DNA may induce STAT3 S754 
phosphorylation in DC to transiently inhibit STAT3 activity and relieve restraints on DC 
activation. Because bone marrow-derived dendritic cells (BMDC) from Stat3fl/fl LysM-Cre+/+ 
mice have an incomplete deletion of STAT3 (Figure 4.1A), I used these cells to approximate the 
inhibitory effect installed by S754 phosphorylation. As expected, DNA transfection induced 
S754 phosphorylation in WT BMDC (Figure 4.1B). Cytosolic DNA-induced DC maturation was 
not affected by reduced STAT3 levels, as shown by comparable upregulation of stimulatory co-
receptors CD80 and CD86 in WT and KO BMDC (Figure 4.1C; Table 4.1). Both WT and KO 
BMDC were able to maintain homeostatic T cell proliferation in a co-culture system in the 
absence of foreign antigen or stimulation, while DNA-stimulated BMDC had decreased capacity 
to support T cell proliferation, presumably due to T cell anergy in the absence of foreign antigens 
(Figure 4.1D). For future studies, it would be of interest to determine the capacity of DNA-
stimulated STAT3 KO BMDC to activate T cells following pulsing with foreign antigens or 
tumor-derived neoantigens. An increase in T cell proliferation induced by STAT3 KO BMDC 
will justify further investigations on the regulation of STAT3 activity in DC in the tumor 
microenvironment. 
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Functional loss of the cytosolic DNA pathway is often observed in some commonly used 
cell-lines in the laboratory and primary tumors, suggesting that loss of this pathway confers 
survival or proliferation advantage to the cancers in vivo and perhaps also in vitro. DNA damage, 
which can be caused by aneuploidy in cancer cells or radiation therapy, also activates the 
cytosolic DNA pathway, resulting in IFNβ production and T cell-mediated anti-tumor immunity 
(12,18-21). As a result, functional loss of the cytosolic DNA pathway in cancer provides them an 
advantage in vivo by reducing T cell recruitment and anti-tumor immune responses. However, 
the cell-intrinsic effect of losing the cytosolic DNA pathway has not been fully explored. 
Constitutive STAT3 activation promotes survival and proliferation in many tumors, and 
inhibition of STAT3 activity by S754 phosphorylation would likely be unfavorable to tumors. 
Therefore, functional loss of the cytosolic DNA pathway may also confer a survival advantage at 
a cell-autonomous level by allowing unchecked STAT3 activation. To test this hypothesis, a 
study focusing on whether responsiveness to cytosolic DNA correlates with STAT3 activity in 
cancer cell-lines should be conducted. If genetic ablation of cGAS and STING promotes the 
proliferation and survival in a STAT3-dependent manner in cancer cell-lines that normally 
respond to cytosolic DNA, this would support the aforementioned hypothesis. Additionally, a 
particularly interesting case involves TBK1 and IKKε-dependent cancers, as discussed in 
Chapter 1. It would be of interest to determine if the cytosolic DNA pathway is preferentially 
lost in TBK1-dependent K-RAS transformed cells or IKKε-overexpressing breast cancers. 
With its role in promoting tumorigenesis, STAT3 seems to be a rational target for cancer 
therapeutics. Several strategies have been adopted to develop STAT3 inhibitors, including small 
molecules and phosphotyrosyl peptides that interact with the SH2 domain of STAT3 to directly 
disrupt STAT3 dimerization (13,14,22-25). While these inhibitors demonstrated efficacy in 
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inhibiting STAT3 in vitro, their low affinity and promiscuous substrate specificity pose a major 
challenge for further applications (4-8,26,27). STAT3 decoy oligonucleotides with GAS 
sequences have also been developed to sequester STAT3 from the nucleus, but the potential 
interaction between this decoy and STAT1 may result in confounding effects (9,28,29). 
Targeting the upstream kinases that activate STAT3 is another approach. For example, 
Ruxolitinib is a JAK1/JAK2-specific inhibitor approved by FDA for myelofibrosis, but it also 
showed promising results in leukemia patients in a phase II trial through STAT3 inhibition 
(10,11,30).  AG490, another JAK2-specific inhibitor, selectively blocks STAT3-driven 
proliferation and induces cell death in several cancer cell-lines (12,31-33), In tumors with EGFR 
mutation or amplification, the efficacy of anti-EGFR monoclonal antibodies and small molecules 
is also partially mediated by STAT3 inhibition (Reviewed in (13,14,34)). The case for using 
STAT3 inhibitors to treat cancers is also bolstered by the discovery that STAT3 negatively 
regulates the anti-tumor immunity of hematopoietic cells in the tumor microenvironment (2,35-
37). If it is determined that STAT3 S754 phosphorylation by tumor-derived DNA increases the 
ability of DC to activate T cells in the tumor microenvironment, it will provide additional 
arguments to advocate for using STAT3 inhibitors as cancer therapeutics to not only curb tumor 
growth but also augment anti-tumor immunity. 
 
4.2  The Mechanism of STAT3 Inhibition by S754 Phosphorylation 
 My work has demonstrated that S754 STAT3 phosphorylation restricts its transcriptional 
activity, but the molecular mechanism resulting in such inhibition remains to be determined. One 
possible explanation is that S754 phosphorylation modulates STAT3 activity by altering the 
interaction between STAT3 and its co-factors. Of note, one such co-factor, nuclear receptor 
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coactivator 1 (NCOA1), has been shown to promote STAT3 transcriptional activity through 
direct interaction with the amino acids 752-761 of STAT3 (15,38,39). Therefore, I hypothesized 
that S754 phosphorylation will disrupt the interaction between STAT3 and NCOA1. 
Unfortunately, I was unable to detect STAT3-NCOA1 interaction in THP-1 cells under basal 
condition or upon cytosolic DNA stimulation (data not shown). For future directions, comparing 
STAT3 interactomes under basal and cytosolic DNA-stimulated conditions by an unbiased 
proteomics approach may be useful to identify the interactions that are modulated by S754 
phosphorylation. However, there are several caveats in this approach. For instance, the 
percentage of STAT3 being phosphorylated at S754 in a cell will directly affect the quality of the 
results. If only a small fraction of STAT3 in the cell is phosphorylated at S754, interactions that 
are phospho-S754-dependent may not be sufficiently distinguished from the background. The 
use of phosphomimetic mutants, S754D or S754E, may be an alternative solution, but it also 
risks the possibility of not fully reflecting the structural and functional change of a 
phosphorylation and fail to capture some of the phospho-S754-dependent interactions. 
The decreased Y705 phosphorylation in S754 phosphorylated STAT3 and S754D mutant 
is in fact more consistent with another hypothesis regarding the stability of STAT3 dimers. 
Mutational analyses demonstrated that the cluster of negatively charged acidic amino acids in the 
C terminus destabilize STAT3 dimers, and the stability of STAT3 dimers correlates with the 
level of Y705 phosphorylation, since the phosphorylated residue is likely more vulnerable to 
phosphatases when the dimers are less stable (16,40). Therefore, the additional negative charges 
introduced by S754 phosphorylation may further destabilize STAT3 dimers, thereby reducing the 
level of Y705 phosphorylation and its transcriptional activity. To test this hypothesis, I assessed 
IL-6-induced STAT3 dimerization by blue native-PAGE (BN-PAGE). Because inactive STAT3 
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can also exist as dimers due to interactions mediated by the NTDs, deltaNTD-STAT3 (amino 
acids 125-770) was used to evaluate the effect of S754 phosphorylation on dimerization 
mediated by phospho-Y705 and the SH2 domain. As expected, S754D mutant showed a mild 
decreased in dimerization upon IL-6 stimulation (Figure 4.2). Because the stability of STAT3 
dimers has a direct impact on its DNA binding activity (17,40), future investigations will focus 
on the dimer stability of full-length STAT3, and hence the DNA binding activity, in the presence 
or absence of S754 phosphorylation. 
 
4.3  Concluding Remarks 
 In the first part of my dissertation (Chapter 2), I showed that myeloid STAT3 deficiency 
results in reduced IFNα expression in macrophages, and impaired DC and NK cell activation, 
making the mice more susceptible to HSV-1 infection. This demonstrates that STAT3 is required 
to mount an efficient anti-viral response through innate immunity at the early stage of viral 
infection, and may partially explain the susceptibility of human AD-HIES patients to 
herpesviruses. In the second part of my dissertation (Chapter 3), I revealed that cytosolic DNA 
restrains STAT3 activation through a TBK1-mediated inhibitory phosphorylation, and expanded 
our knowledge of regulation of STAT3 activity by PTM. In summary, my research contributes to 
our understanding of the roles and regulation of STAT3 in innate immunity. The discovery that 
STAT3 activity can be fine-tuned by the cytosolic DNA pathway also reveals potential 
implications in cancer biology. Future studies will be built on these findings to continue 
investigating the molecular mechanism of STAT3 regulation, and to explore the means of 
manipulating STAT3 activity for therapeutic purposes. 
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4.4  Materials and Methods 
BMDC differentiation. The bone marrows of 12-week-old female mice were isolated as 
described in Chapter 2. Cells were cultured in BMDC differentiation media (RPMI 1640 with 
10% FBS and Pen/Strep, supplemented with 20 ng/ml of GM-CSF (Biolegend)). On day 2 and 4 
after isolation, half of the media was gently removed and replaced with fresh media. BMDC in 
suspension were collected after 6 days and analyzed by flow cytometry as >60% CD11c+. 
T cell isolation. Splenic T cells were isolated from a 13-week-old wild-type male mouse 
by magnetic T cell isolation kit (Stemcell #19851) according to manufecturer’s instruction. The 
viability and purity (CD3+) of isolated T cells were determined by flow cytometry as > 95%. The 
T cells were labeled with 2.5 µM of CFSE (Biolegend) at a density of 3.5x106 cells/ml at room 
temperature for 4 minutes, and washed three times with RPMI1640 with 10% FBS. 
DC and T cell co-culture. BMDC were plated in 96-well round bottom plates at 2.5x105 
or 0.5x105 cells/well in 100 µl of BMDC media, and were left untreated or transfected with 
VACV70mer at 2 µg/ml with lipofectamine 2000 (Thermo Fisher) as described in Chapter 3. 
Next day, freshly isolated and CFSE-labeled T cells were added to the BMDC at 0.5x105 
cells/well in 100 µl of RPMI 1640 with 10% FBS and Pen/Strep. After 4 days of culture, cells 
were analyzed by flow cytometry, and viable proliferated T cells (DAPI-CD3+) were gated by 
their lower CFSE intensity. 
BN-PAGE.  BN-PAGE was carried out as described in (41). Flag-deltaNTD-STAT3 
(amino acids 125-770) reconstituted MEFs were serum-starved overnight and treated with 100 
U/ml of mouse IL-6 (Biolegend) for 30 minutes or left untreated. Cells were lysed with BN lysis 
buffer with 0.5% Triton X-100, protease inhibitor cocktail (Promega), phosphatase inhibitor 
cocktail (Sigma), and 1 µM of pervanadate, and spun at 13000 rpm at 4°C for 10 minutes to 
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remove cell debris. The protein concentration of the supernatants was adjusted to ~2-3 mg/ml 
with BN lysis buffer, followed by mixing with 2% Coomassie G-250 (Sigma) to a final 
detergent-to-Coomassie ratio of 8:1. Twenty-five µg of protein per sample was resolved in 10% 
BN-PAGE gel with 3.6% stacking gel together with native protein markers (Life Technology). 
The proteins were transferred to PVDF membranes by wet transfer (25 mM Tris, 192 mM 
glycine, 0.01% SDS, 10% methanol for 2h at 70V) and proceeded with regular immunoblotting 
using STAT3 antibody (Cell Signaling Technology #9139) 
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Figure 4.1  Cytosolic DNA induces STAT3 S754 phosphorylation and promotes DC 
maturation 
(A) Immunoblotting of STAT3 in GM-CSF-differentiated BMDC derived from WT or KO mice. 
No differentiation block of BMDC was observed in Stat3 knockout cells (not shown) (B) WT 
BMDC were transfected with increasing concentration of VACV70mer for 3 hours or left 
untreated, and analyzed by immunoblotting. (C) WT and KO BMDC were transfected with 2 
µg/ml of VACV70mer or left untreated, and analyzed by flow cytometry to determine CD80 and 
CD86 expression after one day. Shaded area: untreated BMDC; Solid line: DNA-transfected 
BMDC. Data are representative of 3 mice per group. (D) WT or KO BMDC were transfected 
with 2 µg/ml of VACV70mer or left untreated. After 1 day of culture, BMDC were co-cultured 
with CFSE-labeled T cells at different ratios for 4 days. Proliferated T cells were determined by 
lower CFSE intensity. Data are shown as mean with standard deviation with 3 mice per 
genotype. 
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Figure 4.2  S754 phosphomimetic interferes with STAT3 dimerization 
MEFs reconstituted with Flag-deltaNTD-STAT3 were treated with 100 U/ml of mouse IL-6 for 
30 minutes, and lysates were subjected to BN-PAGE to analyze STAT3 dimerization. 
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Table 4.1  Upregulation of stimulatory co-receptors in BMDC by DNA transfection 
Mouse (n=3) Treatment % CD80+ %CD86+ 
WT Ctrl 42.7 ± 4.46 46.5 ± 5.48 
KO Ctrl 41.1 ± 1.31 46.3 ± 1.79 
WT DNA 76.9 ± 1.33 90.9 ± 1.55 
KO DNA 72.2 ± 2.15 95.1 ± 0.81 
BMDC from STAT3 WT or KO mice were transfected with 2 µg/ml of VACV70mer or left 
untreated for a day. The percentage of CD80+ or CD86+ cells in CD11c+ population was 
determined by flow cytometry. 
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